

















		 This	 thesis	 details	 our	 early	 efforts	 towards	 the	 discovery	 of	 polymeric	 and	macromolecular	platforms	for	the	targeted	delivery	of	sensors	and	actuators	to	specific	cell	types	 in	 the	 living	 brain	 tissue.	 Chapter	 1	 of	 this	 thesis	 discusses	 the	 small	 molecule	tropane	 tag	 chosen	as	a	homing	 ligand	and	 the	dopamine	 transporter	 (DAT)	chosen	as	a	cellular	target,	as	well	as	the	synthesis	of	new	tropane-based	molecular	tags	for	evaluation	in	 cultured	 human	DAT	 (hDAT)-expressing	 cells	 and	 targeting	 in	 brain	 tissue.	 Chapter	 2	discusses	the	results	obtained	from	evaluation	of	the	new	tropane	tags	in	hDAT-expressing	and	hNET-exressing	cells,	 including	early	results	 from	the	 first	example	of	a	DAT-specific	voltage	sensing	dye.	In	Chapter	3,	we	discuss	the	principles	governing	molecular	targeting	of	 probes	 in	 the	 living	 brain	 tissue.	 Part	 I	 of	 Chapter	 3	 gives	 important	 background	necessary	 for	 understanding	 some	 of	 the	 complexities	 involved	 in	 targeting	 chemical	probes	 to	 specific	 sites	 in	 living	 brain	 tissue.	 Part	 II	 of	 Chapter	 3	 discusses	 early	 results	obtained	from	targeting	of	our	tropane	tags	in	living	brain	tissue.	We	provide,	perhaps,	the	first	example	of	a	binding-site	barrier	effect	 in	healthy	tissue	and	demonstrate	successful	delivery	of	 a	moderate-sized	protein,	neutravidin,	 to	dopaminergic	 axons.	Chapter	3	 also	discusses	 preliminary	 results	 demonstrating	 the	 behavior	 of	 our	 small	molecule	 tag	 and	tagged	quantum	dot	construct	in	the	living	mouse	brain.	Studies	of	our	tagged	polymers	in	cultured	 cells	 and	 our	work	 thus	 far	 in	 the	 brain	 suggest	which	 polymers	may	 be	most	
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I. INTRODUCTION			 		 Targeted	 therapeutics	 for	 the	 treatment	 of	 brain	 disorders	 such	 as	 Parkinson’s	disease,	schizophrenia,	and	depression	presents	a	dream	of	medical	neuroscience	that	is	slowly	becoming	reality.	Technologies	at	the	interface	of	distinct	scientific	disciplines	are	continuously	being	developed,	enabling	us	to	better	understand	the	complexities	of	brain	function	 and	 how	 these	 complexities	 manifest	 themselves	 in	 phenotypic	 traits	 such	 as	personality	 and	behavior.	 Cell-type	 selective	molecular	probes	 are	highly	desirable,	 but	they	 are	 scarce.	 To	 our	 knowledge,	 few	 have	 been	 developed	 for	 application	 in	 brain	tissue.	 Tropane-	 and	 piperazine-	 analogues	 such	 as	 DaTScan	 and	 GBR-12935,	respectively,	 have	 been	 developed	 as	 small	 molecular	 tags	 for	 the	 dopamine	transporter.1–3	 The	 tropane-based	 analogues,	 specifically,	 have	 been	 employed	 as	 small	molecular	 tracers	 for	 use	 in	 positron	 emission	 tomography4	 (PET)	 or	 single-photon	emission	 computed	 tomography	 (SPECT),5,6	 and	 have	 helped	 uncover	 changes	 in	 brain	structure	 associated	 with	 disease,	 such	 as	 DA	 neuronal	 axon	 degeneration	 in	Parkinson’s.2,7	 Few	 fluorescent	 probes	 exist	 for	 use	 in	 brain	 tissue.	 Fluorescent	 false	neurotransmitters	(FFNs)	developed	in	our	lab8,9	and	voltage-sensing	dyes10–12	have	been	developed	for	the	study	of	certain	aspects	of	cellular	function	such	as	neurotransmission	and	membrane	potential	 changes,	 respectively.	NeuO,	a	 fluorescent	 chemical	probe,	has	been	 developed	 for	 labeling	 and	 imaging	 live	 neurons.13	 Further,	 CDr3	 (a	 fluorescent,	BODIPY-based	 dye)	 has	 been	 found	 selective	 for	 FABP7-expressing	 neural	 stem	 cells.14	These	 molecular	 probes	 have	 been	 important	 in	 unraveling	 the	 relationship	 between	cellular	 expression/function	 and	 normal	 physiology/disease	 etiology.	 Further	
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development	of	novel,	cell-type	selective	probes	for	studying	the	brain	is	indispensible	for	advancing	biomedical	research.		
I.1	 The	Dopamine	Transporter	(DAT)	The	 dopamine	 transporter	 (DAT)	 is	 a	 high	 affinity	 plasma	 membrane	 biogenic	amine	transporter	belonging	to	the	family	of	neurotransmitter:sodium	symporters	(NSS)	[also	 known	 as	 of	 the	 solute	 carrier	 6	 (SLC6)	 family],	 that	 additionally	 includes	transporters	for	norepinephrine	(NET),	serotonin	(SERT),	GABA,	and	glycine.3,15,16	DAT	is	responsible	 for	regulating	DA	neurotransmission	by	mediating	reuptake	of	DA	 from	the	synaptic	cleft	and	perisynaptic	space.3,16	DAT	is	known	to	play	a	central	role	in	regulating	presynaptic	function	and	is	a	primary	regulator	of	dopaminergic	neurotransmission	in	the	CNS.3,15	 As	 such,	 DAT	 serves	 as	 an	 established	 target	 for	many	 pharmacological	 agents	affecting	brain	function,	such	as	cocaine,	Ritalin,	and	amphetamine.	The	presence	of	DAT	in	 the	striatum	appears	 to	be	 related	 to	 the	self-administration	of	 cocaine.17	 In	 fact,	 the	identification	 of	 DAT	 as	 the	 receptor	 target	 for	 cocaine	 helped	 underpin	 the	 dopamine	theory	of	addiction.3	Additionally,	changes	in	levels	of	DAT	expression	and	dopaminergic	innervation	 have	 been	 correlated	 with	 brain	 disorders	 such	 as	 Parkinson’s	 disease,2,7	major	depression,	and	ADHD,	further	underlining	the	importance	of	this	molecular	target.	In	 many	 of	 these	 studies,	 DAT-selective	 ligands	 were	 employed	 using	 in	 vivo	 brain	imaging	techniques	such	as	single-photon	emission	tomography	(SPECT)18	and	positron	emission	 tomography	 (PET).4,5,17,19	 Thus,	 studies	 involving	 both	 DAT	 substrates	 and	inhibitors	as	ligands	have	been	vital	in	our	understanding	of	DAT	regulation	and	function	at	the	molecular	level.			
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Though	DAT	has	been	highly	 studied	and	DAT-specific	 ligands	have	been	widely	employed,	many	questions	still	 remain	regarding	 the	 role	of	DAT	 in	etiology	of	disease.	Thus,	DAT	still	presents	an	important	target	for	understanding	the	molecular	mechanisms	(and	 therapies)	 involved	 in	 brain	 disorders	 associated	with	 dysregulation	 of	 dopamine	neurotransmission.	 Design	 of	 a	 DAT-selective,	 fluorescence-based	 contrast	 agent	employed	 for	 targeted	 delivery	 of	 sensors	 and	 actuators	 to	 sites	 of	 dopaminergic	innervation	 could	 be	 useful	 in	 furthering	 our	 understanding	 of	 DAT	 function	 in	 both	healthy	and	diseased	tissue.		
I.2		 Small	Molecule	Ligands	for	the	Dopamine	Transporter			 There	are	a	number	of	synthetic	and	naturally	occurring	small	molecules	that	act	as	potent	inhibitors	of	the	dopamine	transporter	(Table	1-1).	Many	of	these	ligands	have	some	 selectivity	 for	 DAT	 over	 other	 monoamine	 transporters	 NET	 and	 SERT.	 Ligands	such	 as	 GBR-12935	 and	 cocaine	 derivative	 WIN	 35,428	 have	 been	 used	 clinically	 to	determine	the	extent	of	dopaminergic	innervation	in	rat	and	ex	vivo	human	of	Parkinson’s	disease.1,2	In	our	search	for	a	DAT-specific	ligand,	we	desired	a	small	molecule	that	would	be	amenable	to	chemical	modifications,	and	whose	modifications	would	be	well	tolerated	by	 DAT.	 The	 piperazine	 derivative	 GBR-12935	 appeared	 a	 good	 candidate,	 but	 limited	work	 had	 been	published	 on	 few	derivatives	 and	 their	 activity	 at	DAT.	 By	 contrast,	 far	more	was	known	about	analogues	of	cocaine	and	their	activity	at	DAT.5,20–23	As	such,	we	chose	these	small	molecule	tropane	ligands	for	design	of	our	DAT-specific	VSDs.	
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I.3		 Rational	Design	of	Tropane-Based	DAT-Selective	Probes		








































DAT Inhibitors Ki (nM)
Table	1-1.	Small	molecule	inhibitors	for	DAT.	Ki	values	correspond	to	inhibition	of	dopamine	uptake.	Table	modified	from	Torres	GE	et	al,	Nature	Reviews,	2003.		
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stimulant	 or	 antidepressant.20	 Since	 then,	 a	 wide	 variety	 of	 tropane	 analogues	 derived	from	 cocaine	 have	 been	 synthesized,	 with	 varying	 selectivity	 at	 and	 affinities	 for	 DAT,	NET,	and	SERT.5,19,21,22,24,25		A	large	number	of	synthetic	and	naturally	occurring	tropane	analogues	exist	with	modifications	at	many	of	the	eight	positions	on	the	tropane	ring	structure22,26	(Figure	1-





3. Direct attachment of phenyl ring to tropane core structure 
i) Dramatically increases stimulant activity and binding affinity 
ii) R substituent makes modest contribution to binding and inhibition 
iii) 3,4-dichloro substitution here increases DAT potency and selectivity over NET/SERT
2. Modification at Ester functionality 
i) Important for DAT recognition 
ii) Important for H-bonding (though not necessary) 
iii) Hydrophobic interactions at DAT binding site suggested by SAR 
iv) Large functional groups and extended linker chains well-tolerated
1. Modification at bridged amine 
i) SAR suggests necessary for ionic or H-bonding 
ii) Large functional groups and extended 











revealed	that	reduction	of	the	nitrogen	basicity	at	position	8	by	addition	of	an	N-sulfonyl	group	 still	 produced	 potent	 DAT	 inhibitors	 at	 physiological	 conditions,	 despite	 the	amine’s	 inability	 to	 be	 protonated.22,27	 Further,	 SAR	 studies	 revealed	 that	 position	 2	 is	critical	 for	DAT	recognition	such	that	a	change	 in	stereochemistry	 from	2β	(axial)	 to	2α	(equatorial)	 significantly	 impacts,	 if	 not	 completely	 eliminates,	 potency	 at	 DAT.20	 SAR	studies	have	also	shown	that	direct	attachment	of	the	phenyl	ring	to	position	3	to	produce	phenyl	 tropane	 analogues	 dramatically	 increases	 the	 stimulant	 activity	 and	 affinity	 for	DAT.20	Substitutions	on	the	phenyl	ring	has	a	less	pronounced	affect	on	DAT	affinity.20,22	Since	 the	 phenyl	 tropanes	 lack	 the	 3-benzoate	 ester	 group	 of	 cocaine,	 they	 are	presumably	less	susceptible	to	degradation	by	esterases,	which	may	indirectly	contribute	to	their	measurable	affinity.28	Lastly,	changing	the	stereochemistry	at	positions	1	and	5	of	cocaine	from	(R,S)	to	its	enantiomer	(S,R)	altogether	eliminates	activity	at	DAT.20		The	dopamine	transporter	has	been	studied	for	decades	by	PET	and	SPECT	using	tropane-based	probes	as	in	vivo	tracers.5,7,17,18,29	It	was	not	until	2009,	however,	that	the	first	 tropane-based	 fluorescent	probe	 for	DAT	was	synthesized	and	successfully	used	 in	live	 cultured	 cells.16,24	 Cha,	 Eriksen,	 and	 co-workers	 showed	 that	 modification	 of	 the	tropane	 structure	 by	 attachment	 of	 a	 fluorophore	 at	 either	 positions	 8	 or	 2	 was	 well	tolerated,24	 with	 both	 activity	 and	 selectivity	 at	 DAT	 retained	 compared	 to	 the	 parent	analogue,	dichloropane	(Figure	1-2).		Given	this	information	and	the	extent	to	which	the	tropane-DAT	system	has	been	mapped,	we	chose	to	synthesize	a	fluorescent	tropane	analogue	that	would	1)	allow	us	to	specifically	 label	 and	 visualize	 DAT	 and	 2)	 allow	 us	 to	 target	 and	 sense	 membrane	potential	changes	at	individual	DAT-expressing	cells.			
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I.4		 The	 Norepinephrine	 Transporter	 (NET)	 as	 an	 In	 Vivo	 Target	 for	 Tropane-
Based	Chemical	Tags	In	 addition	 to	 DAT,	 our	 lab	 is	 also	 interested	 in	 the	 norepinephrine	 transporter	(NET)	 owing	 to	 its	 importance	 as	 a	 target	 for	 pharmacological	 agents	 such	 as	antidepressants	 and	 the	 importance	 of	 its	 cognate	 transporter	 norepinephrine	 (NE)	 in	
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2 62 [37-105] 194 [153-244] 392 [286-537] 18 [15-22]






















Figure	 1-2.	 Activity	 of	 3β-dichlorophenyl	 tropane	 (dichloropane)	 and	 fluorescent	 analogues	 at	












mood	 regulation.3	 NET	 is	 expressed	 in	 noradrenergic	 neurons	 originating	 in	 the	 locus	coeruleus,	which	project	to	many	regions	including	the	hippocampus	and	cortex.30,31	Like	DAT,	 NET	 relies	 on	 the	 electrochemical	 gradient	 across	 the	 plasma	 membrane	 to	transport	 monoamine	 substrates;	 though,	 only	 one	 Na+	 and	 one	 Cl-	 ion	 are	 co-transported	along	with	the	organic	substrates.3,30			




II.1		 Synthesis	of	DAT-specific	Tropane	Ligand		The	 process	 towards	 the	 preparation	 of	 DAT-specific	 imaging	 agents,	 voltage	sensors,	 polymers,	 and	 nanoparticles	 began	 with	 the	 synthesis	 of	 the	 tropane	 alkaloid	intermediate	 5b.	 Intermediate	 5b	 and	 similar	 analogues	 can	 be	 accessed	 through	 two	distinct	synthetic	routes.	The	first	route,	‘Route	1,’	employs	a	challenging	and	low-yielding	conjugate	addition	of	an	aromatic	Grignard	reagent	to	an	ene	ester	intermediate	(Figure	
1-3).25	The	second	route,	 ‘Route	2,’	employs	a	robust	Suzuki	coupling	reaction	to	access	an	ene	ester	intermediate	that	is	subsequently	reduced	via	samarium(II)	iodide,	the	latter	step	also	leading	to	modest	yields	of	the	desired	5b	isomer	(Figure	1-4).33	Since	both	Routes	1	and	2	share	the	common	intermediate	2-(R)-tropinone	methyl	ester	 2,	 we	 elected	 to	 pursue	 the	 enantioselective	 synthesis	 of	 2	 via	 published	procedure.34	Thus,	tropinone	1	was	enantioselectively	deprotonated	via	chiral	base	A,	and	the	nonracemic	enolate	was	subsequently	 reacted	with	methyl	 cyanoformate	 (Mandar’s	reagent)	 to	yield	 tropinone	methyl	 ester	2	 in	55%	yield	and	near	excellent	ee	(91%	by	chiral	HPLC;	92%	published34)	(Figure	1-3).	Though	a	high	optical	purity	was	obtained,	the	total	yield	for	the	product	was	below	the	89%	published34	yield.	Since	the	TLC	of	the	crude	reaction	 indicated	 the	presence	of	only	product	and	base	A,	my	 former	colleague	Dr.	Adam	Henke	and	I	decided	to	delve	further	into	the	potential	causes	for	material	loss.	We	discovered	that	the	product	was	very	soluble	in	water	and	4	extractions	using	organic	solvent	(CHCl3),	as	literature	procedure	describes,	resulted	in	recovery	of	only	half	of	the	expected	 product	mass.	 Additional	 extractions,	 upwards	 of	 12	 ×	 20	mL	 for	 a	 1.5-gram	tropinone	 reaction	 scale,	 were	 necessary	 to	 recover	 sufficient	 amount	 of	 product.	 The	
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contrast	 with	 the	 observations	 of	 Carroll	 and	 co-workers,36	 but	 is	 consistent	 with	 the	observations	of	Clarke	et	al.20	Published	yields	for	the	desired	2β,3β-dichloropane	5b	are	low	(~16.7%)25,	and	it	is	well	known20	that	uncatalyzed	Michael	additions	using	Grignard	reagents	 are	 particularly	 difficult	 and	 often	 very	 low-yielding.	 Further,	 α,β-unsaturated	esters	 are	 known	 to	 be	 unreactive	Michael	 acceptors	 towards	 Grignard	 reagents,	 often	having	 poor	 conversions.25,37	 We	 thought	 that	 addition	 of	 a	 catalytic	 amount	 of	 a	copper(I)	 salt	 would	 aid	 the	 reaction	 via	 in-situ	 formation	 of	 a	 Gillman	 reagent	 thus	facilitating	the	formation	of	product.	As	such,	I	attempted	the	conjugate	addition	reaction	in	 the	presence	of	 catalytic	 amount	 of	 Cu(I)	 Iodide,	 but	 observed	no	 change	 in	product	ratios.	Optimizing	reaction	conditions	for	the	conjugate	addition	was	not	further	explored	since	an	alternate	synthetic	route	was	known19	(Figure	1-4).		
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The	 second	 route,	 adapted	 from	 Meltzer	 and	 co-workers19,22	 (Figure	 1-4),	 was	successfully	employed	towards	the	synthesis	of	intermediate	5b.	Non-racemic	keto	ester	
2-(R)	 was	 converted	 to	 the	 enol	 triflate	 3	 in	 good	 yield	 (70-80%).	 Suzuki	 coupling	between	3	and	commercially	available	3,4-dichlorophenylboronic	acid	afforded	4	in	good	to	excellent	yields	(85-91%).	The	resulting	(2-carbomethoxy-3-dichlorophenyl)-ene	ester	































































isolated	 in	 ~70-90%	 yield,	 often	 in	 a	 1:2	 ratio	 favoring	 the	 2β,3α-diastereoisomer.	Stereoisomers	 5a	 and	 5b	 were	 separated	 by	 2	 rounds	 of	 column	 chromatography	 to	afford	pure	5b	in	~35%	yield.		Before	proceeding	with	the	remaining	synthetic	steps,	we	wanted	to	confirm	that	the	 absolute	 stereochemistry	 of	 the	 isomer	 we	 chose	 for	 subsequent	 chemical	modifications	was	the	same	as	that	of	cocaine.	Comparison	of	proton	NMR	data	obtained	for	 both	 isomers	 with	 published	 values	 suggested	 which	 isomer	 corresponded	 to	 the	2β,3β-isomer	 and	 which	 was	 2β,3α-isomer.	 It	 appeared	 to	 us,	 however,	 that	 most	published	NMR	assignments	had	not	been	done	rigorously	but,	 instead,	were	reliant	on	other	published	NMR	assignments.	To	our	knowledge,	only	1	original	paper	referenced	a	crystal	structure	that	was	used	to	confirm	the	stereochemistry	of	a	similar	isomer.	Other	stereochemical	 assignments	 were	 based	 on	 cocaine.	 Due	 to	 the	 dearth	 of	 rigorous	stereochemical	 characterization	 of	 these	 diastereomers,	 we	 confirmed	 the	 structure	 of	one	 isomer	 to	 be	 the	 2β,3β-isomer	 using	 analytical	 1D,	 2D,	 and	 NOE	 NMR	 techniques	(Experimental	 Section).	 Additionally,	 with	 the	 help	 of	 Dr.	 Serge	 Ruccollo,	 a	 former	graduate	student	in	the	Parkin	lab,	we	obtained	a	crystal	structure	to	confirm	the	absolute	stereochemistry	 of	 the	 product.	 Both	2β,3β-	 and	2β,3α-stereoisomers	 of	 phenyltropane	are	reportedly	active	at	DAT,21,26,33	many	with	high	DAT	affinity,	although	selectivity	 for	DAT	over	other	MATs	varies.	However,	we	chose	to	proceed	with	a	single	chemical	entity,	the	2β,3β-isomer,	to	maintain	the	chemical	homogeneity	of	future	probes.		After	 confirming	 the	 stereochemistry	 of	 the	 desired	 2β,3β-isomer,	 I	 confidently	proceeded	with	the	subsequent	synthetic	steps	to	obtain	key	intermediate	7	(Figure	1-4).	Demethylation	 of	 the	 tertiary	 nitrogen	 in	 5b	 yielded	 the	 secondary	 amine	 6,	 and	
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subsequent	 nitrogen	 alkylation	 afforded	 the	 dopamine	 transporter	 ligand	 (DATL)	 7	 in	good	 yield.	 Because	 we	 would	 be	 delivering	 various	 loads	 to	 the	 cell-surface	 receptor	DAT,	a	medium	chain-length	was	introduced	to	minimize	interference	with	DAT	binding.	BOC	deprotection	of	the	linker	gave	the	corresponding	primary	amine,	which	was	readily	converted	to	the	desired	probes	(see	below).		
II.2		 Racemic	Synthesis	and	Chiral	Resolution	of	Tropinone	Methyl	Ester,	2	





1. NaH, THF, rt
2. L-(+)-Tartaric Acid, EtOH
3. i. Recrystallization in Acetone/H20 


































II.3		 Synthesis	 of	 high-affinity	 targeted	 ligands	 for	 the	 Dopamine	 Transporter	
from	2β-Carbomethoxy-3β-(3,4-dichlorophenyl)-tropane	intermediate	7	
	 As	 discussed	 earlier	 in	 this	 chapter,	 the	 parent	 dichloropane	 structure	 5b	 was	chosen	for	our	targeted	delivery	program	because	of	its	high	nanomolar	apparent	binding	affinity	 for	 DAT	 and	 its	 demonstrated	 tolerance	 for	 chemical	 modification	 at	 both	 the	bridgehead	amino	and	2-methyl	ester	positions.24	In	addition	to	its	high	apparent	binding	affinity	 at	 DAT,	 dichloropane	 5b	 also	 demonstrated	 nanomolar	 apparent	 affinities	 for	neurotransmitter	 transporters	 NET	 (norepinephrine	 transporter)	 and	 SERT	 (serotonin	transporter)	 in	 uptake	 inhibition	 experiments	 in	 transfected	 COS-7	 cells24;	 thus,	selectivity	of	5b	 for	DAT	over	NET/SERT	was	poor.	Modification	of	5b	by	addition	of	a	linker	 +	 fluorophore	 at	 the	 bridgehead	 amino	 position,	 however,	 resulted	 in	 a	 3-fold	increase	in	selectivity	for	NET	and	a	6-fold	increase	in	selectivity	for	SERT	as	compared	to	DAT.24	 Achieving	 selectivity	 between	 DAT,	 NET,	 and	 SERT	 is	 ideal	 but	 may	 be	 less	important	 in	 systems	 where	 only	 one	 of	 the	 transporters	 is	 expressed,	 such	 as	 in	 the	striatum	 (DAT).	 For	 in	 vivo	 targeted	 delivery	 to	 the	 whole,	 intact	 brain,	 however,	transporter	selectivity	is	desirable	to	enable	the	study	of	specific	systems	and	to	minimize	background	 staining.	 Nonetheless,	 because	 of	 its	 optimal	 DAT	 affinity	 and	 tolerance	 to	chemical	 modifications,	 we	 envisioned	 the	 design	 and	 synthesis	 of	 a	 library	 of	 2β-carbomethoxy-3β-(3,4-dichlorophenyl)-tropane-based	 constructs	 suitable	 for	 selective	delivery	of	a	multitude	of	chemical	entities,	ranging	from	small	molecular	probes	to	large	nanoparticles,	 to	 dopaminergic	 cells	 in	 the	 brain	 (Figure	 1-7).	 As	 such,	 we	 began	 our	
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Multivalent dextran polymers/FeO nanoparticle









































































1. TFA:CH2Cl2, 2:1 
























activated	ester	(Invitrogen)	afforded	ECN127	 in	good	yield	(82%).	Similarly,	 reaction	of	amine	salt	with	the	activated	ester	functionalities	of	NHBoc-PEG5000-Succinimidyl	valerate	(Laysan	 Bio)	 or	 Biotin-PEG5000-Succinimidyl	 valerate	 (Laysan	 Bio)	 yielded	9	 and	10	 in	good	 (82%)	 and	 near-quantitative	 (97%)	 yields,	 respectively,	 after	 purification	 by	dialysis.	 The	 final	 probes	 were	 analyzed	 and	 their	 identity	 confirmed	 by	 NMR	spectroscopy.	






































































































































DIPEA, DMF, CH2Cl2, 





















DIPEA, DMF, CH2Cl2, 









































Figure	 1-11.	 Synthesis	 of	 conjugated	 ANEP	 system	 16	 through	 Heck	 coupling	 of	 pyridine	 with	 6-diethylamino-2-naphthylbromide	and	subsequent	syntheses	of	DAT-specific	voltage	sensing	dyes	(VSD):	small	molecule	DATL-VSD	and	polymeric	ECN067	(DATL-PEG3400-VSD).	DATL	=	Ligand	for	the	Dopamine	transporter;	PEG	=	poly(ethyleneglycol).	
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III. EXPERIMENTAL	SECTION			









additional	proton	peaks	apparent	 in	 the	 spectrum	of	 the	product.]	m/z:	198.24;	 [α]21.6D	+18.98°	(c	=	1.04,	MeOH);	lit	([α]21D	+18.6°	(c	=	1,	MeOH)	(Meltzer	et	al,	J	Med	Chem,	1994,	37(13);	 ([α]20D	 +18.3°	 (c	 =	 1,	 MeOH)	 (Findlay	 SP	 et	 al,	 JOC,	 1957,	 22:1385-93;	 ([α]25D	+25.4°	 (c	 =	 1,	 MeOH);36	 93%	 ee	 by	 analytical	 HPLC	 (Chiracel	 OD	 column);	 93%	 ee	(Majewski	et	al).	
Methyl	 (1R)-8-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-8-






unstable	 under	 acidic	 silica	 gel	 column	 chromatography,	 the	 crude	 product	 was	 used	without	further	purification.	The	crude	product	was	obtained	as	a	relatively	pure	amber-colored	 oil:	 1.47	 g,	 83%	 yield.	 1H-NMR	 (400MHz,	 CDCl3):	 δ	 1.54—1.63	 (m,	 1H,	H-4α),	1.95—2.00	(m,	2H),	2.12—2.25	(m,	2H),	2.40	(s,	NCH3),	2.85	(dd,	1H,	H-4β),	3.41—3.44	(m,	1H,	H-5),	3.82	(s,	OCH3),	3.93	(m,	1H,	H-1).	m/z:	330.08.	
Methyl	 (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-methyl-8-

















	Nordicholorpane:	Dichloropane	5b	(0.25g,	0.76	mmol)	was	dissolved	in	 neat	 1-chloroethyl	 chloroformate	 (0.6	 mL,	 5.46	mmol),	 and	 the	 reaction	 vessel	 was	fitted	with	a	reflux	condenser	and	refluxed	at	95	°C	(oil	bath	temperature)	for	2.5	hours.	The	reaction	was	allowed	to	cool	to	room	temperature	then	concentrated	under	reduced	pressure	to	remove	all	volatiles.	To	the	concentrate	was	added	MeOH	(5	mL,	anhydrous).	The	resulting	solution	was	allowed	to	reflux	for	an	additional	1	hour	at	75	°C,	after	which	the	 volatiles	were	 evaporated.	 The	 crude	 reaction	mixture	was	 dissolved	 in	 CH2Cl2	 (10	mL)	 then	 washed	 with	 a	 saturated	 solution	 of	 NaHCO3	 (2	 x	 5	 mL),	 dried	 (Na2SO4),	concentrated,	and	purified	by	flash	column	chromatography	(5%	Et3N	in	Et2O;	then	10%	Et3N	in	Et2O)	to	afford	a	clear	oil:	0.21	g	(90%)	1H-NMR	(CDCl3)	δ:	1.26	(m,	1H),	1.54—1.90	(m,	4H),	1.95—2.16	(m,	2H),	2.24—2.42	(m,	2H),	3.14	(m,	1H),	3.44	(s,	1H,	NH),	3.59	(s,	3H,	OCH3),	3.64	(m,	1H),	3.72	(m,	1H),	7.04	(dd,	1H,	ArH),	7.28	(d,	1H,	ArH),	7.33	(m,	1H,	ArH).	m/z:	313.92	











	Dopamine	 Transporter	 Ligand	 (DATL,	 7):	Nordichloropane	6	(0.21	g,	0.67	mmol)	was	dissolved	in	DMF	(5	mL,	anhydrous)	and	the	solution	 degassed	 with	 Argon	 streaming	 (bubbling)	 for	 5	 minutes.	 4-(Boc-amino)butyl	bromide	 (0.25	 g,	 1	mmol)	 was	 then	 added	 followed	 by	 K2CO3	 (0.19	 g,	 1.4	mmol).	 The	reaction	 vessel	 was	 then	 flushed	with	 Argon,	 sealed	 off,	 and	 heated	 to	 65	 °C	 (oil	 bath	temperature).	 The	 reaction	 was	 stirred	 at	 65	 °C	 for	 12	 hours.	 The	 mixture	 was	 then	cooled	to	room	temperature,	basified	to	pH	10	(NH4OH)	and	the	aqueous	layer	extracted	with	EtOAc	 (2	 x	5	mL).	The	 combined	organic	 layers	were	dried	 (Na2SO4),	 filtered,	 and	concentrated	 under	 reduced	 pressure	 to	 yield	 a	 crude	 mixture	 that	 was	 purified	 by	column	 chromatography	 (0.1%	 Et3N,	 5%	MeOH,	 CH2Cl2)	 to	 yield	 a	 white	 solid:	 0.21	 g	(63%).	1H	NMR	(400MHz,	CDCl3):	δ	1.38—1.73	(m,	12H),	1.95—2.14	(m,	2H),	2.20—2.31	(m,	 2H),	 2.50—2.57	 (ddd,	 1H),	 2.87—2.97	 (m,	 3H),	 3.10	 (m,	 2H),	 3.38	 (m,	 1H),	 3.50	 (s,	OCH3),	3.68	(m,	1H),	4.83	(broad	s,	NHBoc),	7.09	(dd,	1H,	ArH),	7.31—7.33	(m,	2H,	ArH).		














DATL	 7	 (11.5	 mg,	 20	 μmol)	 in	 CH2Cl2	 (0.5	 mL)	 was	 added	 TFA	 (1	 mL)	 at	 0	 °C.	 The	resulting	 solution	 was	 allowed	 to	 stir	 at	 0	 °C	 for	 1	 hr,	 after	 which	 the	 volatiles	 were	evaporated.	 The	 purity	 of	 the	 resulting	 TFA	 amine	 salt	 was	 confirmed	 by	 1H	 NMR	(400MHz,	CDCl3):	δ	1.67—1.86	(m,	4H),	2.03	(m,	1H),	2.12—2.24	(m,	2H),	2.27—2.44	(m,	2H),	2.57	(m,	1H),	2.98—3.02	(m,	2H),	3.09—3.13	(m,	2H),	3.22	(m,	1H),	3.35	(s,	OCH3),	3.65	(m,	1H),	4.10	(m,	1H),	4.32	(m,	1H),	4.83	(broad	s,	NHBoc),	7.12	(dd,	1H,	ArH),	7.39	(d,	1H,	ArH),	7.49	(d,	1H,	ArH).			




















35	 °C.	 The	 reaction	 was	 then	 placed	 under	 high	 vacuum	 to	 concentrate	 the	 reaction	mixture.	The	remaining	~0.5	mL	volume	was	then	loaded	onto	a	silica	gel	column	and	the	product	purified	by	 flash	 column	chromatography	 (SiO2	deactivated	by	Et3N;	0.5%Et3N-5%	MeOH-CHCl3	followed	by	0.5%	Et3N-10%	MeOH-CHCl3)	to	yield	a	hot	pink	solid:	11.1	mg,	82%.	1H	NMR	(400MHz,	CDCl3):	δ	2.90—2.97	(m,	2H),	3.08—3.17	(m,	6H),	3.25	(m,	2H),	3.39—3.42	(m,	2H),	3.50	(s,	OCH3),	3.57	(m,	8H),	4.16	(m,	1H,	H-5),	4.51	(m,	1H,	H-1),	6.26	 (broad	 s,	 1H,	 CONH),	 6.70—6.72	 (m,	 2H),	 6.82—6.88	 (m,	 2H,	 ArH),	 7.10	 (dd,	 1H,	ArCl2H),	7.20—7.24	(m,	3H,	ArH),	7.29	(dd,	1H,	ArH),	7.37	(dkmm,	1H,	ArH),	7.87	(broad	s,	1H,	SO2NH),	8.07	(dd,	1H,	ArH),	8.84	(d,	1H,	ArH).	MALDI-TOF:	1039.41			













added	rhodamine	red-X	activated	ester	(3	mg,	4.4	μmol;	Invitrogen)	and	DIPEA	(0.01	mL,	53	μmol).	The	resulting	mixture	was	heated	to	35	°C	for	12	hours,	after	which	DMF	was	evaporated	 under	 high	 vacuum.	 The	 crude	 product	 was	 purified	 by	 flash	 column	chromatography	 (SiO2	 deactivated	 by	 Et3N;	 0.5%Et3N-5%	 MeOH-CHCl3)	 to	 yield	 a	 hot	pink	solid:	5.2	mg,	57%.	1H	NMR	(400MHz,	MeOH):	1.53—1.65	(m,	10H),	1.69—1.79	(m,	2H),	1.94	(d,	1H),	2.02	(ddd,	1H),	2.1—2.23	(m,	6H),	2.61	(broad	s,	2H),	2.76	(ddd,	1H),	3—3.09	(m,	14H),	3.16—3.22	(m,	3H),	3.47—3.52	(m,	2H),	3.53	(s,	3H),	3.71	(quart,	9H),	3.96	(d,	1H),	6.96	(d,	2H),	7.04	(dd,	2H),	7.09	(dd,	1H),	7.14	(d,	2H),	7.33	(d,	1H),	7.47—7.54	(dd,	2H),	8.12	(d,	1H),	8.68	(d,	1H).					












PEG5000-BIO,	 10):	DIPEA	(12.5	μL,	72	μmol)	was	added	to	a	solution	of	TFA	amine	salt	(76	mg,	12	μmol)	 in	DMF	(0.5	mL)	and	 the	resulting	solution	was	stirred	 for	5	minutes	under	Argon.	Biotin-PEG5000-SVA	(52	mg,	10	μmol;	Laysan	Bio)	was	then	added	and	the	reaction	vessel	 sealed	and	stirred	at	35	 °C	overnight.	After	overnight	 stirring,	DMF	was	evaporated	from	the	vial	under	high	vacuum,	and	the	resulting	crude	mixture	dissolved	in	water	 (2.0	mL),	added	 to	a	Slide-A-Lyzer	dialysis	cassette	 (2,000	MWCO),	 then	dialyzed	overnight	in	DDi	H2O.	After	overnight	dialysis,	the	solution	was	removed	from	the	cassette	and	evaporated	to	dryness	under	high	vacuum	to	afford	an	off	white	solid:	53.3	mg,	97%.												


























	Pseudoecgonine	 methyl	 ester	 (3b):	 NaBH4	(11.3	 mg,	 0.3	 mmol)	was	added	to	a	stirring	solution	of	tropinone	methyl	ester	2	(118	mg,	0.6	mmol)	in	MeOH	(3	mL)	at	0	°C.	The	reaction	was	allowed	to	proceed	for	3	hours	at	0	°C	after	which	it	was	concentrated	 under	 reduced	 pressure	 and	 the	 crude	material	 purified	 by	 flash	 column	chromatography	 (10%	 MeOH	 in	 CH2Cl2,	 then	 50%MeOH	 in	 CHCl3)	 to	 afford	 19.7	 mg	(17%)	of	 the	product	as	a	white	solid.	 1H	NMR	(400MHz,	CDCl3):	δ	1.53—1.57	(m,	2H),	1.72—2.00	(m,	4H),	2.38	(s,	3H,	NCH3),	2.72	(dd,	1H),	3.22	(m,	1H),	3.46	(dd,	1H),	3.73	(s,	3H,	OCH3),	4.11	(m,	1H,	H-3).	Rf		0.33	(10%	MeOH	in	CH2Cl2)				










	6-ethylamino-2-naphthylbromide	 (12):	 To	 a	 solution	 of	 6-bromo-2-naphthol	 (1	 g,	 4.48	mmol)	 dissolved	 in	water	 (10	mL)	 in	 a	 thick-walled,	 high	pressure	 flask	 was	 added	 Na2S2O5	 (1.65	 g,	 8.68	 mmol)	 and	 NaOH	 (0.89	 g,	 22	 mmol).	Ethylamine	 hydrochloride	 (1.79	 g,	 22	 mmol)	 was	 then	 added,	 and	 the	 reaction	 vessel	tightly	 sealed	and	heated	 to	140	 °C	with	vigorous	 stirring.	The	 reaction	was	allowed	 to	proceed	for	5	days	at	140	°C,	with	TLC	monitoring,	after	which	it	was	cooled	on	ice	then	poured	into	a	solution	of	NaOH	(2M,	20	mL).	The	precipitate	was	filtered	and	allowed	to	air	 dry	 until	 constant	 mass	 to	 yield	 a	 brick-red	 solid	 (717	mg,	 64%)	 as	 a	 1:1	 ratio	 of	product	 and	 starting	 material	 (as	 determined	 by	 1H-NMR).	 The	 crude	 material	 was	purified	by	 flash	column	chromatography	(5%	EtOAC	 in	hexanes)	 to	yield	12	as	a	brick	red	solid.		









acetaldehyde	 (23	 μl,	 0.4	 mmol)	 were	 added.	 The	 reaction	 was	 stirred	 for	 12	 hrs	(overnight)	then	diluted	with	CH2Cl2	(5	mL),	after	which	it	was	washed	with	NaHCO3	(1	x	10	mL),	water	(1	x	10	mL)	and	brine	(1	x	10	mL).	The	combined	organic	layer	was	then	dried	(MgSO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	mixture	was	purified	 by	 flash	 column	 chromatography	 (5%	 EtOAC	 in	 hexanes)	 to	 yield	 a	 white,	crystalline	solid:	52	mg,	48%.	1H	NMR	(400MHz,	MeOD):	δ	1.27	(t,	6H),	3.54	(q,	4H),	6.94	(d,	1H),	7.23	(dd,	1H),	7.40	(dd,	1H),	7.56	(d,	1H),	7.66	(d,	1H),	7.84	(d,	1H).		






	1-((2-phthalimido)ethyl)	 picolinium	 bromide	 (15):	 2-bromoethylphthalimide	(0.508	g,	0.42	mmol)	was	dissolved	in	NMP	(5	mL)	under	Ar,	and	to	this	solution	was	added	4-picoline	(0.1	mL,	0.21	mmol).	The	reaction	vessel	was	sealed	and	 heated	 to	 90	 °C	 for	 23	 hrs,	 after	 which	 it	 was	 cooled	 to	 room	 temperature.	 The	reaction	was	 then	diluted	with	EtOAc	 to	precipitate	 the	product	and	dissolve	NMP.	The	product	was	obtained	as	 a	 light	pink	 solid:	 0.232	g,	 65%.	 1H-NMR:	 (400MHz,	DMSO):	 δ	2.58	(s,	3H),	3.35	4.12	(t,	2H),	4.76	(t,	2H),	7.82	(m,	4H,	phthH),	7.96	(d,	2H),	9.01	(d,	2H).	











	ANEP	VSD	 (17):	Diethyl	ANEP	16	 (58	mg,	0.19	mmol)	and	3-bromopropyl	 isothiocyanate	(0.09	mL,	0.77	mmol)	were	dissolved	 in	DMF	(0.4	mL)	then	CH3CN	was	added	(4	mL)	and	the	reaction	heated	for	20	hrs	at	80	°C.	The	reaction	 was	 then	 stopped	 and	 solvents	 evaporated	 first	 under	 reduced	 pressure	 (to	evaporate	 CH3CN)	 then	 under	 high	 vacuum	 (to	 evaporate	 remaining	 DMF).	 The	 crude	mixture	was	recrystallized	with	EtOAc-Hexanes	(3:1)	to	yield	17	as	a	nearly	black	solid:	74	mg,	81%.	1H-NMR:	(400MHz,	solvent):	δ	1.16	(t,	6H),	2.31	(quin,	2H),	3.48	(quart,	2H),	3.86	(t,	2H),	4.56	(t,	2H),	6.92	(broad	s,	1H),	7.14	(broad	d,	1H),	7.45	(d,	1H),	7.67	(d,	1H),	7.75	(t,	1H),	7.96	(s,	1H),	8.09	(d,	1H),	8.19	(d,	1H),	8.88	(d,	1H).	IR:	2102	cm-1,	2187	cm-1,	-N=C=S;	1581	cm-1	C=C.		


























resulting	 solution	was	 stirred	 for	1	hr	at	0	 °C	 then	warmed	 to	 room	 temperature,	 after	which	the	volatiles,	including	excess	TFA,	were	evaporated	under	reduced	pressure.	The	residue	was	dissolved	in	a	2:1	mixture	of	CH2Cl2	(1	mL)	and	DMF	(0.5	mL),	and	DIPEA	(80	μL)	 added.	 This	 solution	 was	 allowed	 to	 stir	 for	 5	 min	 at	 room	 temperature	 with	 Ar	bubbling	through	the	solution.	After	5	min,	a	pre-made	solution	of	17	(8	mg,	17	μmol)	and	DMAP	 (catalytic	 amount)	 in	 CH2Cl2	 (0.5	 mL)	 was	 added	 to	 the	 reaction	 mixture.	 The	reaction	was	then	sealed	and	stirred	at	room	temperature	overnight,	then	heated	to	and	stirred	at	35	°C	for	3	hrs.	CH2Cl2	was	then	evaporated	and	the	resulting	mixture	in	DMF	was	 loaded	 directly	 into	 a	 dialysis	 cassette	 (Slide-A-Lyzer,	 2,000	MWCO)	 and	 dialyzed	against	water	 (3	 changes,	 150	mL	each)	 for	24	hrs.	After	dialysis,	 the	 aqueous	 solution	was	 collected	 and	 evaporated	 to	 dryness	 to	 afford	 a	 red	 solid:	 9.2	 mg,	 38%.	Distinguishable	 1H-NMR	 peaks:	 (400MHz,	 CDCl3):	 δ	 4.67	 (t,	 3H),	 6.84	 (d,	 1H,	 naphtH),	7.08—7.12	(m,	4H),	7.31	(d,	1H,	ArClH),	7.61	(d,	2H,	naphtH),	7.72	(d,	1H,	naphtH),	7.79	(d,	1H,	naphtH)	7.86	(d,	2H,	pyrH-3,5),	8.3	(d,	2H,	pyrH-2,6).			
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I. INTRODUCTION		 Overall	macroscopic	brain	 function	results	 from	the	convergence	of	 inputs	at	 the	cellular	 and	 molecular	 levels.	 Important	 to	 proper	 cellular	 function	 are	 the	 small	molecules	 and	macromolecules	 (e.g.	 ions,	 neurotransmitters,	 proteins,	 lipids)	 that	 both	constitute	 and	 traverse	 the	 biological	 cell	 membrane.	 Biological	 membranes	 are	functional,	 discrete	 organelles	 that	 separate	 cells	 from	 one	 another—creating	 an	intracellular	compartment	and	extracellular	space—and	partition	the	intracellular	space	into	 different	 discrete	 compartments.1	 A	 large	 and	 significant	 electrostatic	 potential	difference	exists	across	many	biological	membranes,	resulting	from	an	ion	concentration	gradient	generated	by	the	membrane-bound	Na+/K+	ATPase.1,2	This	membrane	potential	drives	directional	transport	of	a	variety	of	compounds,	including	neurotransmitters2,	thus	making	it	critical	to	many	physiological	functions.		The	microelectrode3	and	patch	clamp	techniques	have	enabled	 the	measurement	of	membrane	 potential	 changes	 at	 the	 level	 of	 individual	 neurons.4	 As	 such,	 they	 have	been	 essential	 in	 our	 understanding	 of	 neuronal	 function.	 These	 techniques	 have	excellent	temporal	resolution	but,	as	a	function	of	electrode	size	(now	well	under	1	μm),1	are	limited	spatially	to	cells	and	organelles	with	large	diameters	(on	the	order	of	μm).1,4,5	Targeting	of	individual	neurons	using	genetically	encoded	fluorescent	proteins	is	another	method	 for	measuring	membrane	 potential	 changes	 in	 targeted	 cells.	Measurements	 of	membrane	potential	using	genetically	encoded	proteins	such	as	green	fluorescent	protein	(GFP)	 and	 yellow	 fluorescent	 protein	 (YFP)	 have	 grown	 in	 popularity	 but	 this	method	requires	 time-consuming	 genetic	 manipulations,	 including	 expression	 of	 the	 fused	
	 62	
genetically	encoded	protein	that	can	perturb	the	natural	state	of	the	cell.6,7	Further,	not	all	animal	models	or	cell	types	are	readily	given	to	genetic	manipulation.	
I.1	 Development	 of	 cell-type	 specific	 dyes	 for	 visualization	 of	 membrane	
potential	changes	in	the	brain		The	possibility	of	measuring	membrane	potential	using	optical	methods	was	first	proposed	by	Cohen	and	co-workers	in	mid-19685,8	with	the	proposition	that	shifts	in	the	absorbance	spectra	of	chloroplasts	were	correlated	with	changes	in	membrane	potential.	Later	 that	 same	 year,	 Tasaki	 and	 co-workers	 offered	 experimental	 evidence	 for	 such	changes,	demonstrating	fluorescence	changes	in	response	to	nerve	excitation	in	nervous	tissue.9	 In	 spite	 of	 this,	 it	 was	 not	 until	 ca.	 1971	 that	 the	 search	 for	 fluorescent	 dyes	suitable	 for	 optical	measurements	 of	membrane	 potential	 began.5	 In	 a	 combined	 effort	between	 chemists	 and	 neurobiologists,	 over	 1000	 fluorescent	 dyes	 were	 screened	 in	19785,	 and	 more	 than	 half	 that	 number	 have	 since	 been	 developed	 and	 identified	 as	responsive	 to	 changes	 in	 membrane	 potential.	 Some	 of	 these	 dyes,	 such	 as	 the	 well-known	and	widely	used	hemicyanine	dye	di-4-ANEPPS10,	have	found	use	in	a	wide	variety	of	 cellular	 applications.	 Other	 more	 sensitive	 dyes,	 such	 as	 ANNINE-611,12,	 can	 achieve	fractional	changes	in	fluorescence	(ΔF/F)	of	up	to	50%/100	mV,	a	marked	improvement	of	 the	 fractional	 fluorescence	 changes	 obtained	 for	 earlier	 dyes	 (1-10%/100	 mV).13–15	Still,	more	synthetic	dyes,	such	as	Tsien’s	PeT	probe16,	are	being	developed	and	employed	to	sense	fast	membrane	potential	changes	with	even	larger	measurable	readouts	(ΔF/F).	Further,	 these	 voltage-sensitive	 dyes	 (VSDs)	 can	 be	 used	 to	 detect	 fast	 (microsecond)	
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membrane	potential	changes,	such	as	action	potentials	 in	excitable	cells1,5,17,	 that	can	be	corroborated	using	other	techniques.		In	 spite	 of	 these	 advancements,	 extrinsically	 applied	 VSDs	 are	 limited	 in	application	to	cultured	cells	or	time-consuming	intracellular	loading	techniques	that	also	result	 in	 staining	 of	 intracellular	 membrane	 compartments.12	 Application	 of	 these	nonspecific	 VSDs	 in	 highly	 heterogeneous	 systems	 such	 as	 brain	 tissue	would	 result	 in	staining	of	all	cell	types,	occluding	the	study	of	membrane	potential	changes	of	individual	neuronal	cells	or	specific	cell	types.	Development	of	a	cell-type	specific	voltage	sensitive	dye	(VSD)	would	allow	optical	measurements	of	membrane	potential	in	specific	cell	types	in	 the	 brain	 tissue	 without	 genetic	 manipulation.	 Such	 a	 probe	 would	 present	 a	 less	invasive,	 less	time-consuming	method	for	recordings	of	membrane	potential	at	the	level	of	individual	neurons.		Under	 the	umbrella	 of	 the	 synaptic	 imaging	project	 jointly	headed	by	 the	 Sames	and	 Sulzer	 research	 groups,	 we	 sought	 to	 design	 a	 probe	 that	 could	 be	 used	 to	 label	specific,	 individual	 cells	while	concomitantly	measuring	membrane	potential	 changes	at	those	cells.	We	made	several	considerations	in	the	design	of	such	a	probe.	We	envisioned	a	 probe	 that,	 on	 one	 end,	would	be	 specific	 for	 a	membrane-bound	 receptor	 expressed	exclusively	 on	 specific	 cell	 types	 thus	 enabling	 it	 to	 act	 as	 a	 ‘homing	 ligand’	 to	 that	receptor.	 At	 the	 other	 end	 of	 the	 probe,	 we	 envisioned	 the	 attachment	 of	 a	 dual-functioning	 small	 molecule	 that	 would	 both	 enable	 detection	 by	 fluorescence	 imaging	techniques	 and	 enable	 measurement	 of	 membrane	 potential	 changes.	 Such	 dual	properties	 exist	 with	 established	 voltage	 sensitive	 dyes.	 We	 also	 envisioned	 that	 the	homing	 ligand	 and	 VSD	 would	 be	 connected	 through	 a	 flexible	 molecular	 spacer	 long	
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II.1	 Visualization	 of	 the	 Human	 Dopamine	 Transporter	 (hDAT)	 in	 Living	 EM4	
Cells	by	Fluorescent	Tropane	Analogues				 Before	proceeding	with	 the	 syntheses	 of	 a	 library	 of	DAT-specific	 tropane-based	sensors	and	polymers	 for	 targeted	delivery	 to	dopaminergic	cells	 in	brain	 tissue,	 it	was	necessary	that	we	reproduce18	the	visualization	of	hDAT	in	our	hDAT	expression	system.	The	EM4	cell	 line	stably	expressing	hDAT	was	used	as	a	model	experimental	system	for	determining	DAT	 labeling.	EM4	cells	 are	a	modified	HEK293	cell	 line	 stably	 transfected	with	a	macrophage	scavenger	receptor	that	results	 in	better	adherence	to	tissue	culture	plates	than	regular	HEK293	cells.19,20	Vector	transfected	EM4	cells	served	as	a	control	for	non-DAT-specific	staining.		The	 hDAT-EM4	 cells	 were	 pretreated	 in	 experimental	 medium	 (Dulbecco’s	minimum	eagle	medium,	DMEM)	containing	vehicle	(DMSO)	or	2	μM	nomifensine,	a	high	affinity21	DAT/NET	antagonist,	for	1	hr	at	37°C	and	5%	CO2.	Following	pretreatment,	the	cells	were	incubated	with	10	nM	ECN127	for	30	min	at	room	temperature.	After	several	rinse	 steps	 with	 phosphate-buffered	 saline	 (PBS)	 to	 remove	 any	 unbound	 ECN127,	specific	DAT	labeling	was	determined	by	epifluorescence	imaging.	Representative	images	of	 hDAT-specific	 labeling	 of	 ECN127	 are	 shown	 in	 Figure	 1.	 Compared	 to	 the	 vector-transfected	EM4	 controls,	 the	presence	of	membrane-associated	 coronal	 staining	 in	 the	epifluorescence	images	of	hDAT-transfected	cells	reveal	successful	hDAT-specific	labeling	by	ECN127	(Figure	2-2,	B1,	C1).	Pretreatment	with	nomifensine	effectively	blocked	the	interaction	of	ECN127	with	hDAT	(Figure	2-2,	B2	and	C2).	These	results	confirmed	that	the	 fluorescent	 tropane	 ligand	 ECN127	 could	 be	 employed	 to	 specifically	 label	 and	
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visualize	hDAT	in	this	cell	culture	system,	and	suggested	that	subsequent	tropane-based	derivatives	would	also	be	successful.			
Confirming	 the	 interaction	 of	 the	 small	molecule	 ligand	 ECN127	with	 hDAT,	we	wanted	 to	 investigate	 whether	 attachment	 of	 a	 small	 polymer	 such	 as	 poly(ethylene	glycol)	(PEG)	would	impede	tropane	ligand	binding	to	DAT.	Rosenthal	and	co-workers22	previously	 demonstrated	 that	 DAT	 could	 be	 labeled	 in	 cultured	 cells	 by	 a	 polymeric	biotin-PEG5000-tropane	 ligand	 bound	 to	 a	 single	 QDot	 (quantum	 dot)-streptavidin	conjugate.	 Thus,	 several	 PEGylated	 constructs	 bearing	 the	 DAT-specific	 tropane	 ligand	(DATL)	were	 synthesized	 and	 tested	 in	 hDATEM4	 cells:	 Biotinylated	 DATL	mixed	with	







































streptavidin-conjugated	 quantum	 dots	 (DATL-PEG5000-BIO/SA-QD,	 ‘Tagged	 QD”);	Biotinylated	 DATL	 mixed	 with	 Neutravidin	 protein	 and	 BiocytinAlexaFluor594	 (DNB);	and	PSN102	 (DATL-PEG5000-RRX),	 a	PEG	polymer	 analogue	of	ECN127	 synthesized	by	Dr.	 Peter	 Ŝebej	 (Figure	 2-3).	PSN109,	 a	 non-tropane	 tagged	 analogue	 of	 PSN102,	was	CO2,	hDAT-EM4	and	vector-EM4	cells	were	incubated	with	either	0.5	μM	PSN102,	0.5	μm	
PSN109,	or	50	nM	DAT-PEG5000-Biotin/10	nM	SA-QD	in	DMEM	for	30	min,	and	1	μM	DNB	in	DMEM	for	45	min,	at	room	temperature.	Epifluourescence	images	revealed	that	all	of	
Biotin
PEG chainDATL =    Dichloropane + Alkylamino spacer Rhodamine Red X
AlexaFluor594
"Dummy" ligand












































































































































































































































































the	tropane-tagged	probes	successfully	and	selectivity	labeled	DAT,	and	their	interaction	with	DAT	was	blocked	by	2	μM	nomifensine	(Figure	2-4).	PSN109	did	not	label	cells,	as	expected	 for	 this	 non-lipophilic,	 nontargeted	 PEG	 polymer	 control	 (Figure	 2-4).	Additionally,	the	tropane-tagged	analogues	did	not	label	EM4	control	cells	under	the	same	incubation	 and	 imaging	 conditions	 (images	 not	 shown),	 suggesting	 that	 the	 coronal	staining	 pattern	 observed	 in	 the	 hDAT-EM4	 cells	 was	 specific	 to	 DAT.	 These	 results	confirmed	 that	 modification	 of	 the	 tropane	 ring	 system	 with	 a	 large	 PEG	 chain	 at	 the	bridged	nitrogen	position	did	not	occlude	DAT	binding	interaction.					 Next,	 we	 evaluated	 whether	 our	 first	 generation	 DAT-targeted	 voltage-sensitive	dye,	 ECN067	 (DATL-PEG3400-VSD,	 Figure	 2-5,	 panel	 A),	 would	 specifically	 label	 DAT	with	minimal	nonspecific	membrane	staining.	We	hoped	that	the	PEG	spacer	between	the	DAT-specific	 tropane	 and	 the	 lipophilic	 4-(4-diethylaminonaphthylstyryl)-pyridinium	(ANEP)	 dye	 would	 reduce	 the	 lipophilicity	 of	 the	 ANEP	 dye,	 minimizing	 nonspecific	(background)	interactions	with	non-DAT	bearing	membranes	and	increasing	DAT-specific	fluorescence	signal.	Thus,	ECN067	was	applied	to	hDAT-EM4	cells	for	15	min	following	a	45	min	pretreatment	with	vehicle	or	1	μM	nomifensine	as	previously	described.	ECN067	interaction	 with	 hDAT-EM4	 cells	 was	 not	 specific	 to	 DAT,	 as	 pretreatment	 with	 DAT	blocker	nomifensine	did	not	attenuate	its	labeling	(Figure	2-5,	B).	
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As	a	control,	cells	were	treated	for	15	min	with	ANEP	dye	17,	the	voltage	sensitive	dye	not	bearing	any	PEG	modifications	(Figure	2-5,	A).	In	contrast	to	the	doubly	charged,	widely	 used	 ANEP	 dyes	 that	 partition	 the	 cell	 membrane,	 this	 singly	 charged	 VSD	traversed	the	cell	membrane,	staining	cytosolic	membrane	structures	(Figure	2-5,	C).	The	differential	staining	patterns	observed	between	the	more	membrane-bound	ECN067	and	
17,	which	appeared	internalized,	suggests	that	the	PEG	functionality	may	prevent	the	dye	from	 traversing	 the	 cell	 membrane.	 Nonetheless,	 the	 lipophilicity	 of	 the	 ANEP	 dye	occludes	 the	 DAT-specificity	 of	 ECN067.	 My	 project	 collaborators	 are	 currently	
































































II.2		 Potency	of	hDAT	Inhibition	by	Tropane	Derivatives			 Next,	 we	 wanted	 to	 estimate	 the	 hDAT	 affinities	 (Ki	 values)	 of	 the	 small	 and	macromolecular	tropane	ligands.	To	do	this,	we	determined	the	potencies	with	which	the	ligands	inhibited	the	uptake	of	APP+	into	hDAT-transfected	EM4	cells.	Pyridinium	dye	4-(4-dimethylamino)phenyl-1-methylpyridinium	 (APP+)	 is	 a	 fluorescent	 analogue	 of	 1-methyl-4-phenylpyridinium	(MPP+),	a	dopaminergic	neurotoxin	that	induces	permanent	Parkinsonism-like	 symptoms	 in	 humans,	 monkeys,	 and	 mice,23,24	 and	 is	 a	 DAT25/NET	substrate.	 Dose-response	 curves	 were	 obtained	 for	 ECN127,	 PSN102,	 and	 DNB,	 in	separate	experiments.	For	each	experiment,	hDAT-EM4	cells	were	treated	with	the	DAT-selective	probes	 for	either	30	min	 (ECN127)	or	45	min	 (PSN102,	DNB)	 in	experimental	media.	 Within	 the	 same	 experiment,	 hDAT-EM4	 cells	 were	 co-treated	 with	 2	 μM	nomifensine	 in	parallel	 to	determine	the	 level	of	non-specific	 ligand	binding	at	different	concentrations	of	ECN127,	PSN102,	or	DNB.	The	length	of	time	required	for	each	probe	to	reach	equilibrium	binding	of	DAT	was	previously	determined.	Following	treatment	of	the	cells	with	the	tropane	ligands,	APP+	uptake	was	initiated	by	the	addition	of	APP+	(2	μM	final	concentration)	to	the	cells,	and	uptake	was	terminated	after	7	minutes.	After	several	rinses	 with	 PBS,	 APP+	 uptake	 was	 measured	 on	 a	 SynergyH1	 plate	 reader	 at	 the	maximum	fluorescence	excitation/emission	(previously	determined)	for	APP+	(Figure	2-
































































































































































































Measured	IC50	values	for	hDAT	inhibition	were	66.2	±	11.5	nM	for	ECN127	(mean	±	SEM,	 n	 =	 4	 independent	 experiments),	 2.18	 ±	 0.60	 μM	 for	 PSN102	 (n	=	 3	 independent	experiments),	and	0.77	±	0.14	μM	for	DNB	(n	=	3	independent	experiments),	(Figure	2-6,	
D).	 Inhibition	 constants	 (Ki	 values)	were	 calculated	 by	 substitution	 of	 the	 apparent	Km	value	for	APP+	and	the	measured	IC50	values	of	each	tropane-tagged	probe	in	the	Cheng-Prusoff	equation	(Ki=IC50/(1+[S]/Km)).26	Thus,	the	apparent	Ki	values	obtained	were	44.9	nM	 (SE	 interval	 37.2;	 52.9	 nM)	 for	 ECN127,	 1.48	 μM	 (SE	 interval	 1.07;	 1.89	 μM)	 for	PSN102,	and	524.2	nM	(SE	interval	428.9;	619.4	nM)	for	DNB.	The	apparent	Ki	value	for	ECN127	is	in	close	agreement	with	previously	reported	values	obtained	for	[3H]dopamine	uptake	 inhibition	 using	 an	 analogous	 fluorescent	 DAT	 ligand,	 JHC	 1-64	 (see	 Chapter	 1,	Figure	3B,	for	structure	and	Ki	values).18,27		
II.3	 ECN127	is	also	a	High	Affinity	hNET	Ligand		Because	of	the	relative	ease	with	which	the	cortex	can	be	accessed	in	vivo	and	the	expression	 of	 NET	 in	 noradrenergic	 neuronal	 projections	 in	 the	 cortex,	 we	 wanted	 to	evaluate	the	biological	activity	of	the	small	molecule	ligand	ECN127	at	NET	to	determine	its	potential	for	use	in	the	in	vivo	cortex.	Thus,	after	visualizing	the	binding	of	ECN127	to	hNET	in	human	embryonic	kidney	(HEK)	cells	stably	expressing	hNET	(hNET-HEK	cells),	we	then	determined	the	potency	by	which	ECN127	inhibited	APP+	uptake	into	hNET-HEK	cells	 (Figure	 2-7).	 APP+	 uptake	 inhibition	 experiments	 with	 hNET-HEK	 cells	 were	performed	 similar	 to	 that	 for	hDAT-EM4	cells.	The	potency	by	which	ECN127	 inhibited	APP+	uptake	into	hNET-HEK	cells	(IC50	=	97.0	±	12.2	nM,	n	=	2	independent	experiments	in	duplicate,	Figure	 2-7)	was	nearly	similar	 to	 its	potency	at	hDAT	(66.2	±	11.5	nM	for	
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ECN127).	The	apparent	binding	affinity	obtained	 for	ECN127	at	hNET	was	66.0	nM	(SE	interval	74.3;	57.7	nM),	a	1.5-fold	lower	apparent	affinity	than	at	hDAT	but	a	nearly	3-fold	better	apparent	affinity	for	NET	than	the	analogous	fluorescent	DAT	ligand	JHC	1-64	(NET	
Ki	=	194	[153–244]	nM).27	Thus,	ECN127	 is	a	potent	 inhibitor	 for	both	hDAT	and	hNET	and	may	be	suitable	for	in	vivo	use	in	the	cortical	region	of	the	whole,	intact	brain.	
II.4	 Macromolecules,	 polymers,	 and	 ligand	 valency:	 Effects	 on	 Ligand-
Transporter	Potency				ECN127	 differs	 from	 JHC	 1-64	 by	 the	 presence	 of	 two	 additional	 ethylene	 (CH2-CH2)	 units	 in	 the	 linker	 region	 between	 the	 tropane	 nitrogen	 bridge	 and	 rhodamine	fluorophore.	 This	 slight	modification	 does	 not	 appear	 to	 negatively	 affect	 the	 apparent	affinity	 for	 DAT.	 The	 addition	 of	 a	 large	 PEG	 linker	 at	 the	 bridged	 nitrogen	 of	 tropane	does,	however,	significantly	decrease	the	apparent	affinity	of	the	tropane	ligand	for	hDAT	when	compared	to	the	small	molecule	ECN127	(**p	=	0.0086,	PSN102	and	ECN127;	**p	=	0.0019,	DNB	and	ECN127;	two-tailed,	unpaired	t	test).	The	apparent	drop	in	potency	for	


















APP+ Uptake Inhibition at hNET
ECN127 (DATL-RRX)
Figure	 2-7.	 Quantitative	 analysis	 of	
tropane	 ligand	potencies	at	hNET.	Dose	response	 curve	 of	 ECN127	 in	 stably	transfected	hNET-HEK	cells.	(Mean	of	n	=	2	independent	 experiments,	 each	experiment	 performed	 in	 duplicate.	 Error	bars	=	SEM.)	APP+	uptake	is	normalized	to	maximum	 APP+	 fluorescence	 uptake	 in	wells	 with	 lowest	 concentration	 of	inhibitor	 =	 100%.	 IC50	 values	 for	 ECN127	was	determined	to	be	97.0	±	12.2	nM,	
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the	macromolecular	 inhibitors	 is	 likely	 due	 to	 perturbations	 at	 the	 binding	 site	 pocket	resulting	 from	 the	 presence	 of	 the	 PEG	 chain.	 Molecular	 models	 for	 DAT	 binding	 of	cocaine	 analogue	 CFT	 [(−)-2β-carbomethoxy-3β-(4-fluorophenyl)tropane,	 or	 WIN	35,428]	 revealed	 a	 buried	 CFT-binding	 pocket.28	 Disruption	 of	 a	 hydrogen	 bonding	interaction	 between	 residues	 Tyr156-Aspr79	 increased	 permeation	 of	 water	 into	 the	CFT-binding	pocket,28	attenuating	dopamine	(DA)	uptake	activity	yet	stabilizing	the	CFT-binding	site.	Assuming	a	shared	binding	site	between	APP+	and	dopamine,	 it	 is	possible	that	binding	of	ECN127,	similar	in	structure	to	CFT	but	slightly	larger	due	to	the	presence	of	 the	 rhodamine	 fluorophore,	 disrupts	 the	 Tyr156-Asp79	 hydrogen	 bond,	 stabilizing	ECN127	binding	but	attenuating	APP+	uptake.	Thus,	low	concentrations	of	ECN127	would	be	 required	 to	 antagonize	 hDAT.	 Stabilization	 of	 the	 binding	 pocket	 by	 increased	hydration	is	said	to	overcome	the	affect	of	lost	intramolecular	interactions.28	However,	in	the	 case	 of	 the	 pegylated	 ligands,	 the	 presence	 of	 an	 increased	 hydration	 sphere	surrounding	 the	 PEG	 chain,	 which	 also	 results	 in	 an	 increased	 (hydrodynamic)	 radius,	may	 result	 in	 a	 destabilizing	 loss	 of	 intramolecular	 interactions	 for	 DAT,	 making	 DAT	binding	less	favorable.	Higher	concentrations	of	pegylated	ligand	would,	thus,	be	required	to	antagonize	DAT,	as	the	unbound	state	([L]	+	[R]	 	[LR],	L	=	ligand,	R	=	receptor)	would	otherwise	be	more	favored.			 Macromolecular	polymers	are	attractive	as	platforms	for	targeted	delivery	because	of	 their	 ability	 to	 be	 “decorated”	 with	 different	 chemical	 tags	 that	 serve	 a	 variety	 of	functions.	 We	 have	 demonstrated,	 however,	 that	 polymers	 can	 adversely	 affect	 DAT-ligand	 binding	 affinity.	 To	 circumvent	 this	 problem,	 multiple	 tropane	 tags	 may	 be	simultaneously	 conjugated	 to	a	polymer	 to	 recover	affinity.	The	apparent	affinity	of	 the	
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Figure	 2-8.	 Effect	 of	 DATL	 polyvalency	 on	 neutravidin	 protein	 polymer	 affinity	 at	 hDAT.	 Dose	response	curves	of	three	DNB	constructs	with	1,	3,	or	4	DATL	were	evaluated	in	stably	transfected	hDAT-EM4	cells.	Potencies	of	APP+	uptake	inhibition	(IC50)	were	determined	to	be:	0.47	±	0.25	μM	for	4DATL-DNB,	 0.79	 ±	 0.43	 μM	 for	 3DATL-DNB,	 and	 1.57	 ±	 0.91	 μM	 for	 1DATL-DNB	 (mean	 ±	 SEM).	 Curves	 are	plotted	as	mean	of	2	independent	experiments	performed	in	duplicate.	(Error	bars	=	SEM.)	APP+	uptake	is	normalized	to	APP+	fluorescence	uptake	in	control	wells.	
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III. CONCLUSIONS	AND	FUTURE	OUTLOOK:		As	previously	mentioned,	the	first	demonstration	of	a	fluorescent	DAT	ligand	was	JHC	 1-64	 by	 Cha,	 Eriksen	 and	 co-workers.	 Their	 ligand	 was	 used	 to	 visualize	 DAT	 in	cultured	 cells	 and	 to	 study	 PKC-mediated	 DAT	 trafficking	 in	 live	 neurons.	 Similarly,	Rosenthal	 and	 co-workers	 demonstrated	 that	 a	 tropane-based	 ligand	 could	 be	 used	 in	conjunction	with	 streptavidin-conjugated	 quantum	 dots	 to	 visualize	 DAT	 and	 study	 its	trafficking	 in	 living	 cells.	 Here,	 we	 have	 similarly	 used	 tropane-based	 chemical	 tags	 to	visualize	 the	dopamine	transporter.	However,	we	are	 interested	 in	designing	 functional,	tropane-based	chemical	tags	that	not	only	visualize	DAT,	but	also	report	other	biological	activities	 of	 DAT-expressing	 cells.	 As	 stated	 above,	 one	 goal	 of	 this	 project	 is	 to	 design	voltage	 sensitive	 probes	 specific	 for	 the	 dopamine	 transporter.	 Here,	we	 evaluated	 our	first	 tropane-tagged	VSD,	ECN067,	at	hDAT-EM4	cells.	The	high	 lipophilicity	of	 the	VSD,	however,	occluded	the	specificity	for	DAT	such	that	binding	of	ECN067	to	hDAT-EM4	cells	was	not	inhibited	by	DAT	antagonist	nomifensine.	Design	and	biological	evaluation	of	less	lipophilic,	DAT-specific	VSDs	is	currently	underway	in	our	laboratory.						Another	goal	in	our	lab	is	to	design	multifunctional,	polyvalent	chemical	tags	for	in	
vivo	 targeting	 of	 DAT.	 Such	 chemical	 tags	 would	 be	 based	 on	 polymer	 platforms.	Understanding	 how	 different	 aspects	 of	 our	 polymer	 design	 enhance	 or	 impede	 DAT	affinity	 is	 imperative	 to	proper	design.	We	are	designing	polyvalent	polymers	bound	 to	multiple	DAT	ligands.	We	have	shown	that	conjugation	of	a	PEG	polymer	to	the	tropane	ligand	reduces	DAT	binding	affinity,	as	observed	by	direct	comparison	between	ECN127	and	 PSN102.	 It	 is	 not	 known	 how	 the	 PEG	 polymer	 specifically	 perturbs	 tropane	 DAT	binding,	 but	 it	 appears	 that	DAT	 affinity	may	 be	 rescued	 by	 the	 presence	 of	 additional	
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	 Stable,	 HEK-derived	 hDAT-transfected	 EM4	 cell	 lines	 (experimental)	 and	 null-transfected	 EM4	 cell	 lines	 (control)	were	 kindly	 provided	 by	Drs.	 Jonathan	 Javitch	 and	Mark	 Sonders	 of	 the	 Department	 of	 Psychiatry	 at	 Columbia	 University	Medical	 Center. Cells	 were	 grown	 on	 10-cm	 polystyrene	 plates	 (Corning)	 and	 maintained	 in	 complete	growth	 medium	 consisting	 of	 DMEM	 +	 GlutaMAX	 (Thermo	 Fisher	 Scientific)	supplemented	 with	 10%	 Fetal	 Bovine	 Serum	 (FBS,	 Atlanta	 Biologicals),	 100	 U/mL	penicillin	(Invitrogen),	and	100	μg/mL	streptomycin	(Invitrogen).	Cells	were	maintained	at	 37°C	 in	 a	 humidified	 atmosphere	 containing	 5%	 CO2,	 and	 were	 subcultured	approximately	every	3-4	days,	after	reaching	~80%	confluence.	 	For	experiments,	DPBS	(Dulbecco’s	Phosphate	Buffered	Saline:	2.67	mM	KCl,	1.47	mM	KH2PO4,	137.93	mM	NaCl,	and	8.06	mM	Na2HPO4-7H2O;	Thermo	Fisher	Scientific)	was	used	for	rinses.	 
IV.2	 Epifluorescence	Imaging	of	Fluorescent	Tropane	Probes.		EM4	 cells	 expressing	 hDAT	were	 plated	 on	 six-well	 plates	 (Falcon)	 at	 ~2	 ×	 105	cells	per	well	and	grown	in	complete	medium	for	~2	days,	or	plated	on	twelve-well	plates	(Falcon)	 at	 ~1	 ×	 105	 cells	 and	 grown	 in	 complete	 medium	 for	 ~2	 days	 at	 37	 °C,	 in	 a	humidified	atmosphere	containing	5%	CO2,	until	cells	were	at	least	75%	confluent.	On	the	day	of	the	experiment,	growth	medium	was	removed	from	the	wells	by	aspiration	and	the	cells	were	carefully	rinsed	twice	with	DPBS	(2	x	1	mL).	Cells	were	then	pre-treated	with	900	 μL	 of	 experimental	medium	 [DMEM	without	 phenol	 red	 containing	 25	mM	HEPES	(Invitrogen)	supplemented	with	1%	FBS	(Atlanta	Biologicals),	and	1%	of	a	solution	of	100	
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U/mL	 penicillin	 (Invitrogen)	 and	 100	 μg/mL	 streptomycin	 (Invitrogen)]	 containing	nomifensine	 (2	 μM)	 or	DMSO	 (vehicle),	 for	 1	 hour	 at	 37°C	 and	5%	CO2.	 100	μL	 of	 10X	probe	 solutions	 were	 then	 added	 to	 respective	 experimental	 wells	 to	 yield	 final	 (1X)	desired	 concentrations	 of	 probe.	 For	 all	 experiments,	 wells	 treated	 with	 APP+	 (2	 μM)	were	used	as	a	positive	control	 for	hDAT	activity.	APP+	was	 incubated	with	hDAT-EM4	cells	 for	5-10	min	at	 room	temperature	 then	 imaged	without	washing.	Wells	containing	variable	 concentrations	 of	 probe	 were	 incubated	 for	 25	 –	 45	 min	 (depending	 on	 the	probe)	at	room	temperature,	then	rinsed	with	DPBS	(2	x	1	mL),	and	maintained	in	DPBS	(1	 mL)	 for	 epifluorescence	 imaging.	 Images	 were	 acquired	 using	 a	 Leica	 DMI	 4000B	inverted	 epifluorescence	microscope	 equipped	with	 a	 Leica	DFC	 360	 FX	 digital	 camera	controlled	 through	 Leica	 LAS	 AF	 6000E	 software.	 Bright	 field	 and	 fluorescence	 images	were	 acquired	 sequentially	 (BF	 acquisition	 time	 =	 37	 ms).	 Fluorescence	 images	 were	acquired	using	 filter	cubes	 from	Chroma	Technology	Corp:	ET-GFP	 filter	cube	was	used	for	APP+	with	ex	=	470	±	20	nm,	em	=	525	±	25	nm;	a	custom	filter	cube	with	ex	=	580	±	20	nm,	em	=	660	±	25	nm	was	used	to	image	ECN127,	PSN102,	and	DNB;	a	custom	filter	cube	with	 ex	 =	 350	 ±	 25	 nm,	 em	 =	 585	 ±	 30	 nm	was	 used	 to	 image	 the	 quantum	 dot	conjugate.	 Two	 images	 per	 well	 were	 taken	 at	 different	 locations	 of	 each	well.	 Images	mages	 for	 each	 probe	 in	 the	 hDAT-EM4	 cells	 ±	 nomifensine	 and	 vector-EM4	 cells	 ±	nomifensine	 treatments	were	 adjusted	 to	 the	 same	 brightness	 and	 contrast	 level	 using	ImageJ	software	(National	Institutes	of	Health)	in	order	to	properly	compare	the	effect	of	each	treatment	on	the	probe’s	hDAT	binding.		
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IV.3	 Two-step	Imaging	Procedure	for	DATL-PEG5000-BIO/SA-QD	(Tagged	Quantum	
Dot)		 The	cells	were	pre-treated	as	described	above.	After	cells	were	treated	with	DATL-PEG5000-BIO	for	30	min	at	room	temperature,	the	probe-containing	medium	was	removed	by	aspiration	and	cells	were	carefully	rinsed	with	DPBS	(1	×	1	mL).	900	μL	of	a	solution	containing	 either	 10	 nM	 or	 100	 nM	 SA-Qdot	 in	 cold	 DPBS	 was	 then	 added	 to	 the	respective	wells,	and	 the	wells	were	 incubated	 for	10	min	at	4	 °C.	Following	10-minute	incubation,	the	wells	were	aspirated,	rinsed	with	cold	DPBS	(3	x	1	mL),	and	maintained	in	1	mL	DPBS	 for	 imaging.	 Two	 images	per	well	were	 taken	 at	 different	 locations	 of	 each	well.	Images	were	analyzed	as	described	above.	




Measurements)			 To	 determine	 the	 potencies	 of	 DAT	 and	 NET	 inhibition	 by	 the	 various	 tropane-tagged	 probes,	 hDAT-EM4	 or	 hNET-HEK	 cells	 were	 plated	 onto	 poly-D-lysine	 (Sigma-Aldrich,	 0.1	 mg/mL)-coated	 white,	 clear-bottom	 96-well	 fluorescence	 microplates	(Falcon)	at	a	density	of	~48,000-50,000	cells	per	well.	Cells	were	 incubated	for	44	–	48	hours	at	37		 ̊C	in	a	humidified	atmosphere	containing	5%	CO2,	until	fully	confluent.	On	the	day	of	 the	 experiment,	 complete	 growth	medium	was	 removed	by	 aspiration	 and	wells	were	carefully	washed	with	DPBS	(200	μL	per	well).	The	wells	were	then	treated	with	a	90	μL	cocktail	containing	either	probe	+	DMSO	(vehicle)	or	probe	+	nomifensine	(2	μM,	to	determine	 the	 extent	 of	 hDAT-specific	 or	 hNET-specific	 ligand	 binding)	 for	 30	 min	(ECN127)	 or	 40	min	 (PSN102,	DNB)	 at	 room	 temperature.	Uptake	was	 initiated	by	 the	addition	of	10	μL	of	a	10X	solution	of	APP+	for	a	final	concentration	of	2	μM.	Uptake	was	terminated	 after	7-8	minutes	 following	 removal	 of	 the	uptake	medium.	The	wells	were	carefully	 rinsed	 with	 DPBS	 (2	 ×	 200	 μL)	 and	 maintained	 in	 DPBS	 (120	 μL)	 for	fluorescence	uptake	measurements.	The	 fluorescence	uptake	 in	each	well	was	recorded	on	a	plate	 reader	BioTek	Synergy	H1MF	Hybrid	Reader	 (single	 scan	and	3x3	area	 scan,	bottom	read	mode)	with	excitation	and	emission	wavelengths	set	at	436	nm	and	506	nm,	the	 excitation	 and	 emission	 maxima	 for	 APP+,	 respectively.	 The	 specific	 uptake	 was	defined	as	the	overall	fluorescence	uptake	(with	DMSO	vehicle)	subtracted	by	that	in	the	
	 85	
presence	 of	 nomifensine.	 The	 data	 were	 normalized	 then	 fit	 to	 a	 dose	 response	 curve	(three	parameters)	using	GraphPad	Prism	7.	There	were	3	–	4	independent	experiments	performed	 for	 each	 probe	 for	 hDAT	 experiments.	 Two	 independent	 experiments	 were	performed	 for	 ECN127	 uptake	 inhibition	 in	 hNET-HEK	 cells.	 Each	 independent	experiment	consisted	of	duplicate	plates	with	at	least	3	wells	for	each	concentration	per	plate.	
IV.6	 Procedure	for	Km	Determination	of	APP+	in	hDAT-EM4	Cells	 Cells	 stably	 transfected	with	 the	human	dopamine	 transporter	 (hDAT-EM4	cells)	were	seeded	at	a	density	of	5.0	x	104	cells/well	in	white,	clear-bottom	96-well	plates,	and	allowed	to	proliferate	in	growth	medium	for	44	–	48	hrs	at	37	°C	to	reach	confluence.	On	the	day	of	 experiment,	 the	growth	medium	was	aspirated	and	 the	 cells	were	 incubated	with	nomifensine	(2	μM,	100	μL/well)	or	DMSO	vehicle	for	1	hour	at	37°C	and	5%	CO2	in	experimental	medium.	Experimental	medium	(100	μL/well)	containing	either	APP+	or	a	cocktail	of	APP+	and	nomifensine	(2	μM)	was	added.	Because	APP+	is	non-fluorescent	in	water	 or	 experimental	 media,	 continuous	 recordings	 could	 be	 obtained	 without	 first	washing	 the	cells.	The	 fluorescence	uptake	 in	each	well	was	recorded	every	1.5	min	 for	the	required	amount	of	time	on	a	plate	reader	BioTek	Synergy	H1MF	Hybrid	Reader	(3x3	area	 scan,	bottom	read	mode)	with	excitation	and	emission	wavelengths	 set	 at	436	nm	and	 506	 nm,	 respectively.	 The	 specific	 uptake	 was	 defined	 as	 the	 overall	 fluorescence	uptake	 (with	 DMSO	 vehicle)	 subtracted	 by	 that	 in	 the	 presence	 of	 nomifensine.	 The	specific	 uptake	 rates	 were	 linear	 for	 concentrations	 of	 APP+	 up	 to	 50	 μM	 with	 a	corresponding	 incubation	 time	of	7	min.	The	 initial	uptake	rates	 for	each	concentration	
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	 A	 major	 limitation	 in	 the	 treatment	 of	 many	 CNS	 disorders	 is	 the	 successful	delivery	 of	 therapeutics	 to	 the	 brain1.	 Under	 the	 umbrella	 of	 the	 synaptic	 imaging	program	between	the	Sames	and	Sulzer	groups,	we	sought	to	design	a	delivery	platform	that	 would	 be	 used	 to	 selectively	 target	 different	 substances,	 such	 as	 false	 fluorescent	neurotransmitters	 (FFNs),	 therapeutics	 and	 contrast	 agents,	 across	 the	 blood	 brain	barrier	 (BBB),	 through	 the	 brain	 parenchyma,	 and	 to	 the	 specific	 cells	 of	 interest.	 We	envisioned	designing	 a	multifunctional,	 targeted	polymer	 or	macromolecule	 that	would	allow	 us	 to	 “light	 up	 the	 brain”	 so	 that	 visualization	 of	 particular	 regions	 of	 the	 brain	bearing	the	specific	(target)	cells	of	interest	would	be	possible.	Such	a	delivery	platform	would	be	amenable	to	functionalization,	allowing	for	attachment	of	1)	a	BBB-transporting	peptide	or	small	molecule,	2)	a	brain	cell	homing	 ligand,	and	3)	a	deliverable	 “payload”	such	as	a	therapeutic	or	a	imaging	agent.	The	functionalized	construct	should	be	able	to	traverse	 the	 BBB	 and	 enter	 the	 extravascular	 brain	 tissue,	 with	 attachment	 of	 a	 BBB-transporting	peptide	or	small	molecule	facilitating	the	process.	Perhaps	more	important	than	 traversing	 the	 BBB,	 the	 functionalized,	 targeted	 construct	 should	 be	 able	 to	successfully	distribute	 through	 the	very	densely-packed	brain	 tissue	 to	 reach	 the	 target	cells	and,	guided	by	the	homing	ligand,	have	an	increased	probability	of	residence	at	the	target	cells.	The	targeted	construct	should	then	bind	to	specific	receptor(s)	at	the	target	cell	while	minimizing	interactions	with	non-targeted	cells.	Binding	to	the	specific	receptor	
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Figure	3-1.	Cell-specific	targeted	delivery	of	macromolecules	in	brain	tissue.	To	successfully	deliver	targeted	macromolecules	to	specific	cells	of	interest,	macromolecules	must	be	able	to	diffuse	through	the	extracellular	space	(ECS)	of	the	brain	parenchyma,	reach	the	desired	receptors	expressed	on	specific	cells	(A)	 yet	 avoid	 non-specific	 interactions	 with	 cells	 not	 expressing	 the	 receptor	 of	 interest	 (B),	 and	 be	subsequently	 cleared	 from	 the	 tissue	 within	 a	 desirable	 time	 frame.	 Apparent	 diffusion	 coefficient	 in	tissue,	 D*;	 rate	 constants	 kon	 and	 koff	 represent	 the	 rate	 of	 ligand-receptor	 binding	 and	 dissociation,	respectively.			
	 				
Figure 1.
Models of DAT/ligand complexes. (a) Two-dimensional schematic representation of the
human dopamine transporter (hDAT). Colored circles indicate residues that interact with either
dopamine or the cocaine analog CFT in the molecular models. Red circles indicate side-chain
interaction and orange circles indicate backbone interaction. (b) Structure of dopamine, cocaine
and CFT. (c,d) Docked dopamine (c) and CFT (d) in DAT. Transmembrane domains 1, 3, 6
and 8 are shown in various shades of blue; the other transmembrane domains and intra- and
extracellular loops have been removed for clarity. The ligands are shown in green. Sodium and
chloride ions are shown as purple and salmon spheres, respectively. Encircled numbers refer
to the specific interactions motifs. Motif 1 (c), salt bridge interaction between Asp79 and the
protonated amine of dopamine; motif 1 (d), polar interaction between Asp79 and the amine of
CFT; motif 2, aromatic-aromatic stacking interaction between Tyr156 and the catechol ring of
dopamine; motif 3, hydrogen bond between the OH group of Tyr156 and Asp79; motif 4,
hydrophobic-aromatic interaction between Leu80 and Tyr156; motif 5, interaction between
Beuming et al. Page 15


























































B/		 	 				 	 				
Clearance	
	 93	
The	diffusion	properties	of	a	number	of	different	non-targeted	macromolecules	have	been	studied	 in	 brain	 tissue,2–7	 and	 many	 of	 these	 macromolecules	 are	 amenable	 to	functionalization.	 Thus,	 the	 first	 step	 towards	 our	 goal	 of	 designing	 a	 macromolecular	construct	 for	 targeted	 delivery	 was	 to	 survey	 the	 literature	 to	 better	 understand	 the	principles	governing	molecular	diffusion	in	brain	tissue.		
I.1		 The	Brain	Extracellular	Space	(ECS):	Structural	Considerations	for	Targeting		The	brain	tissue	is	a	densely	packed	system	comprised	of	a	network	of	cells	with	varying	widths	(from	5	~100	μm)	and	shapes	(Figure	3-2).	Brain	tissue	is	often	imagined	as	an	aqueous	foam,	with	the	gaseous	phase	(air)	equivalent	to	brain	cells	and	the	liquid	phase	 equivalent	 to	 the	 brain	 extracellular	 space	 (ECS).1,2,4,8	 While	 this	 description	 is	suitable	 at	 a	 basic	 level,	 the	 reality	 is	 that	 the	 brain	 tissue,	 in	 particular	 the	 ECS,	 is	 far	more	complex.	Physiologists	have	long-studied	the	cells	of	the	brain	(neurons,	astrocytes,	microglia	and	oligodendrocytes)	and	as	such,	have	acquired	a	high	level	of	understanding	of	 cellular	activity	and	 function.	However,	 the	properties	of	 the	ECS,	 the	 space	between	the	cells,	are	less	understood.		The	 substances	 that	 diffuse	 or	 are	 transported	 through	 the	BBB	or	paravascular	space	(e.g.,	drugs,	nutrients),	as	well	as	those	locally	synthesized	in	the	brain	parenchyma	(e.g.,	neurotransmitters,	neuromodulators,	and	growth	factors),	must	diffuse	through	the	brain	 ECS	 to	 reach	 their	 cellular	 targets.9	 As	 such,	 the	 ECS	 represents	 an	 important	element	of	the	brain	structure.	Electron	micrographs	show	the	ECS	as	tortuous,	winding	paths	separated	by	cell	bodies.1	Reports	have	estimated	the	average	width	of	the	ECS	to	be	 about	20	nm	 in	most	 regions	of	 the	brain,10,11	 though	estimates	of	 up	 to	35	nm	and	
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greater	 have	 been	 reported.10,12	 Studies	 using	 electron	 microscopy,	 radiotracers,13	 and	iontophoresis14,15	 of	 small	 ions	 have	 estimated	 that	 the	 ECS	 comprises	 ~20%	 of	 total	brain	volume	(ECS	volume	fraction	α	~	0.2)	in	healthy	tissue.	This	value,	however,	can	be	
significantly	reduced	to	as	little	as	~5%	(α	~	0.05)	in	diseased	or	injured	tissue,	such	as	occurs	 in	 terminal	 ischemia,10,16,17	 or	 other	 pathological	 states	 such	 as	 Parkinson’s	disease.16	A	reduction	 in	ECS	volume	fraction	would	result	 in	an	 increased	hindrance	to	diffusion	experienced	by	solutes	present	in	the	brain	interstitial	fluid	(ISF),	the	fluid	that	fills	 the	 ECS.	 This	 could,	 in	 turn,	 significantly	 impact	 the	 movement	 (diffusion	 and	otherwise)	 of	 macromolecular	 therapeutics	 employed	 to	 treat	 the	 disease/injury.3	 One	component	 of	 the	 ECS	 microstructure,	 the	 extracellular	 matrix	 (ECM),	 is	 comprised	 of	long-chain	 macromolecules	 tethered	 to	 cell	 membranes18	 and	 “floating,”	 untethered	
■ IMPORTANT BRAIN EXTRACELLULAR SPACE
PARAMETERS
Brain ECS is sometimes imagined as the liquid phase of a foam,
with the gaseous (air) phase equivalent to brain cells.32 In
reality, the shape and composition of the brain ECS is more
complex. Looking at an electron micrograph of a small section
of cortical neuropil shows the ECS as a tortuous, snaking path
separated by cell bodies and processes having many different
sizes and shapes (Figure 1). The earliest EM studies had
difficulty finding sufficient evidence of any ECS in the brain33
because the manner in which tissue samples were obtained
subjected the tissue to b th ischemia and harsh proc ssing; we
now know ischemia induces significant cell swelling at the
expense of the ECS (i.e., interstitial fluid water rapidly
redistributes from the ECS into the intracellular compartment)
and that subsequent fixation and drying of the tissue may
further complicate the picture.19,34−36 Later EM work
employed better preparative methods, consistently yielding a
small but noticeable brain ECS, estimated to occupy about 5%
of the total tissue volume on average,37 but the effect of
ischemia remained. More specialized EM methods (rapid
freezing followed by freeze substitution), better suited to
preserving the extracellular fluid volume, suggested the ECS
occupied a much larger percentage of total brain volume.19,38
Physiological evidence, e.g., examination of the brain space
occupied by endogenous molecules predominantly confined to
the ECS (e.g., sodium and chloride ions) and results from the
careful measurement of the spread of diffusible substances (i.e.,
diffusion measurements; discussed below) or the spread of
current (impedance measurements) within the brain, also
suggested the normal brain ECS volume was substantially
greater than 5%.20,39 Today, we know that the volume fraction
of the brain ECS (α = ECS volume/total tissue volume) is
about 0.2 (i.e., ECS accounts for about 20% of the total tissue
volume) in most brain regions of normal, adult animals across
multiple species.20,39 Diffusion measurements have proven the
most helpful in the routine measurement of α, yielding many
insights into how this parameter changes over the lifespan in
health and disease. For example, diffusion measurements in
rodents have shown brain ECS volume is much larger in the
early postnatal period immediately following birth (α ∼ 0.4),
that ECS volume declines somewhat with advancing age (α ∼
0.13−0.16 in 17−25 month old mice), and that CNS disease/
injury models can dramatically change the situation (e.g., α ∼
0.05 just minutes after severe ischemia).36,40,41
Many EM studies that examined the volume of brain ECS
also attempted to put a number to the average width or
diameter of the intercellular spaces (dECS), usually reporting a
range between ∼10 and 20 nm.19,37 Brain ECS width is of
obvious importance for drug delivery because it may be
regarded as providing an “upper limit” for the size of a drug or
vector that might be expected to distribute extracellularly within
the neuropil. As with the ECS volume, it has long been
appreciated that the brain ECS width visualized in most
conventionally prepared electron micrographs likely under-
estimates the true dimensions in living tissue. These
dimensions may fluctuate somewhat, but recent in vivo diffusion
measurements obtained in normal, adult rat neocortex have
now established that a sufficient amount of well-connected ECS
has an actual width averaging between 38 and 64 nm.42 This
estimate of dECS was derived by applying hydrodynamic theory
for hindered diffusion (also called restricted diffusion theory) to
quantitative diffusion data obtained in normoxic tissue for
several dextrans (branched polymers of glucose) and inert
Figure 2. Schematic of the brain microenvironment emphasizing the importance of the extracellular space (ECS) in the diffusion of drugs. (A) The
brain microenvironment is a crowded space packed with many different types of cells: astrocytes (green), oligodendrocytes (maroon), neurons
(yellow), and microglia (blue). Brain endothelial cells (pink) and pericytes (light red) are associated with the brain microvessels. Neurites (axonal
and dendritic processes of neurons) and glial processes making up the neuropil are shown in gray. Regardless of whether a drug or other substance
crosses the blood−brain barrier or is directly applied within the brain, distribution within the brain microenvironment usually must involve diffusion
over some distance within the brain ECS. (B) Schematic showing a magnified view of the red box in panel A. ECS width (dECS) and extracellular
matrix (ECM) components such as heparan sulfate proteoglycans (HSPG) may influence the diffusion of biologic drugs having either globular (e.g.,
proteins or viral vectors) or linear configurations (e.g., short interfering RNA (siRNA)). The diffusion of proteins and viruses that bind HSPG may
be enhanced by complexation with heparin, preventing association with endogenous HSPG.44
Molecular Pharmaceutics Review
dx.doi.org/10.1021/mp300495e | Mol. Pharmaceutics 2013, 10, 1492−15041494
Figur 	 3-2.	 The	 brain	 m croenvironment.	 (A)	 The	 brain	 tis ue	 is	 comprised	 of	 closely	 packed	 cells	(gray),	which	 include	 astrocytes	 (green),	 neurons	 (yellow)	 with	myelin	 sheaths	 (maroon)	 and	 neurons	with ut	 yelination	(blue),	and	glia	( roon).	(B)	I set	of	red	box	h ghlighted	in	(A)	showing	a	c ose	up	of	the	extracellular	space	(ECS)	and	extracellular	matrix	(ECM),	and	the	paths	which	diffusing	molecules	must	 cross.	The	orange	 circl 	 repr sents	 the	widt 	of	 the	extracellular	 space	 (the	 space	between	cells),	values	 of	 which	 vary.	 Figure	 is	 adapted	 from	Wolak	 DJ	 and	 Thorne	RG,	 Mol.	 Pharmaceutics	 2013.	 The	diameter	 of	 the	 orange	 circle	 is	 approximately	 20	 –	 35	 nm.	 Diameter	 approximated	 from	 Tao	 and	Nicholson,	PNAS,	2009.			
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molecules	such	as	hyaluronate3,18	that	can	impede	molecular	movement	through	the	ECS.	Many	 other	 components	 are	 still	 unknown	 and	 can	 serve	 as	 additional	 hindrances	 for	diffusing	substances.		Successful	 delivery	 of	 targeted	 therapeutic	 agents	 depends	 on	 their	 abilities	 to	successfully	 spread	 through	 the	 brain	 tissue	 and	 subsequently	 reach	 their	 targets.	 The	successful	 spread	 of	 materials	 is	 dependent	 on	 a	 number	 of	 factors	 intrinsic	 to	 the	material,	 such	 as	 size	 (molecular	weight	 and,	more	 notably,	 hydrodynamic	 radius),	 net	charge,	 shape	 and	 flexibility/rigidity	 of	 the	 compound.	 In	 addition	 to	 these	 intrinsic	factors,	 the	 ability	 of	 a	 material	 to	 successfully	 diffuse	 through	 the	 brain	 extracellular	space	is	influenced	by	external	factors,	namely,	the	local	environment	through	which	the	agent	is	diffusing.	Interactions	with	the	extracellular	matrix	or	cell-surface	receptors,	and	the	volume	fraction	of	the	brain	extracellular	space,	for	example,	can	impact	the	extent	to	which	 these	 agents	 can	 distribute	 to	 and	 through	 the	 brain	 parenchyma.	 Studies	 have	elucidated	 some	 of	 the	 properties	 of	 materials—size,	 shape,	 charge,	 etc.—that	 most	significantly	 impact	 their	 ability	 to	 diffuse	 through	 the	 brain	 extracellular	 space.	Nance	and	 coworkers	 found,	 for	 example,	 that	 polystyrene	 particles	 >40	 nm	 could	 diffuse	through	the	brain	ECS	if	densely	coated	with	bio-inert	poly(ethylene	glycol)	(PEG)	but	not	negatively	charged	carboxylate	(-COOH)	groups.12	Such	work	highlights	the	importance	of	carefully	considering	the	affect	of	surface	modifications	on	charge,	particle	size	and	shape,	and	other	parameters	when	designing	probes	for	brain	tissue	penetration.	These	studies	have	been	invaluable	in	that	they	have	elucidated	the	complexities	of	the	 brain	 extracellular	 space,	 including	 the	 volume	 fraction	 and	 components	 of	 the	extracellular	 matrix;	 they	 have	 increased	 our	 understanding	 of	 the	 ways	 in	 which	
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compounds	 spread	 through	 brain	 tissue	 and	 the	 hindrances	 they	 face;	 and	 they	 have	elucidated	 the	 intrinsic	 properties	 of	 diffusible	 agents	 that	 will	 render	 them	 most	successful	 in	 diffusing	 through	 brain	 tissue.	Many	 reports	 have	 alluded	 to	 the	 effect	 of	binding	 or	 uptake	mechanisms	 on	 slowing	 or	 sequestering	 a	 diffusing	molecule,2,4,5,11,18	but	very	 few	have	actually	 investigated	the	effect	of	 these	mechanisms	on	diffusion	of	a	targeted	substance.	One	study6	found	that	the	in	vivo	diffusion	of	lactoferrin	through	brain	tissue	was	significantly	impeded	by	interactions	with	heparan	sulfate	side	chains	present	in	 the	 ECM.	 These	 ECM	 interactions	 were	 more	 significant	 than	 hydrodynamic	 radius	(size)	 in	 slowing	 the	 diffusion	 of	 lactoferrin	 in	 vivo	when	 compared	 to	 transferrin,	 a	protein	of	similar	size,	shape,	and	function	but	that	does	not	bind	heparan	sulfate.	Despite	these	 studies,	 it	 has	 yet	 to	 be	 demonstrated	 in	 practice	 how	 binding	 to	 cell-surface	receptors	 (or	 “tagging”)	 affects	 the	 diffusion	 and	 targeted	 delivery	 of	 small	 and	macromolecular	therapeutics	to	specific	sites	in	brain	tissue.	In	our	preliminary	work,	we	demonstrate	the	effect	of	both	tagging	and	size	on	the	diffusion	of	organic	molecules	and	the	 ability	 of	 those	 molecules	 to	 target	 specific	 neuronal	 cell	 types	 in	 the	 mammalian	brain	 tissue.	 A	 thorough	 investigation	 of	 these	 properties	 will	 enable	 the	 better	construction	of	targeted	agents,	including	therapeutics,	to	specific	sites	in	brain	tissue.		
I.2		 Theoretical	Diffusion	in	the	Context	of	Brain	ECS	The	 simple	 diffusion	 of	 substances	 at	 the	macroscopic	 level	 can	 be	modeled	 by	Fick’s	law,	that	is	Flux	=	−D	×	concentration	gradient,	which	states	that	the	molar	diffusion	flux	moves	 from	regions	of	high	concentration	 to	regions	of	 lower	concentration	with	a	magnitude	 proportional	 to	 the	 molar	 concentration	 gradient.18	 Formally,	 Fick’s	 law	 is	
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given	by	equation	(1),	where	j	 is	the	molar	diffusion	flux,	D	 is	the	diffusion	coefficient	of	the	substance	in	“free”	medium	(water	or	dilute	agarose),	and	the	first	spatial	derivative	gives	 the	 position	 of	 the	 diffusing	 substance	 in	 space	 (in	 the	 appropriate	 coordinate	system)	 with	 respect	 to	 concentration	 c.18	 In	 simple	 diffusion,	 different	 substances	
present	 in	 the	 same	 medium	 will	 diffuse	 differentially	 according	 to	 their	 respective	diffusion	coefficients.	In	brain	tissue,	however,	the	diffusion	of	molecules	is	governed	by	two	main	factors:	 the	volume	fraction	(α)	of	the	brain	that	 is	comprised	of	ECS,	a	 factor	that	is	extrinsic	to	the	diffusing	molecule	but	can	serve	to	restrict	its	movement;	and	the	intrinsic	 factors	 (such	as	molecular	size,	 shape,	and	charge)	and	extrinsic	hindrances	 to	diffusion	experienced	by	a	molecule	as	it	travels	through	the	brain	ECS,	a	factor	known	as	tortuosity	 (λ).	 The	 tortuosity	 of	 a	 molecule	 is	 given	 by	 λ	 =	 (D/D*)1/2,	 a	 dimensionless	parameter	 that	 is	 the	 square	 root	 of	 the	 ratio	 of	 the	 diffusion	 coefficient	 D	 in	 “free”	medium,	e.g.	water	or	dilute	agarose,	to	the	effective	diffusion	coefficient	D*	of	the	same	molecule	 in	 brain	 tissue.18	 Important	 to	 studying	molecular	 diffusion	 in	 brain	 tissue	 is	estimating	 the	 concentration	of	 the	diffusing	 substance	at	 a	distance	r	 and	 time	 t.	After	several	modifications	to	Fick’s	 law,	including	considerations	for	change	in	concentration	
over	 time,	equation	 (1)	yields	 the	diffusion	equation	 (2),	which	describes	 the	change	 in	concentration	 of	 a	 diffusing	 substance	 as	 a	 function	 of	 time	 t,	 where	D	 is	 the	 diffusion	coefficient	of	the	diffusing	substance,	the	actual	concentration	in	the	interstitial	space11	is	
= D      cj (1)	
(2)			δt =
δC
D     2 C  +  s
= D      cj
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given	by	C,	 and	s	 is	 the	density	of	diffusing	molecules	at	 the	source.	The	position	of	 the	diffusing	 substance	 in	 more	 than	 one	 dimension	 is	 given	 by	 the	 Laplacian	 	 	 	 	 	 ,	 a	generalized	term	for	 the	second	derivative	(second	spatial	derivative).	Equation	(2)	can	be	further	modified	to	describe	diffusion	in	the	ECS	by	the	addition	of	the	parameters	α	and	λ	(equation	(3)),	where	λ	is	incorporated	into	D*,	as	described	above.		
Other	 factors,	 such	 as	 uptake	 and	 binding	mechanisms,	 also	 affect	 the	 extent	 to	which	a	molecular	 substance	 can	diffuse.	Reversible,	non-specific	binding	of	 a	molecule	diffusing	 through	the	brain	ECS	would	 increase	 its	hindrance	 to	diffusion	(tortuosity,	λ)	by	a	factor	proportional	to	the	equilibrium	binding	constant	of	the	molecule	to	the	non-specific	 target.3,19	 A	 substance	 characterized	 by	 a	 free	 aqueous	 diffusion	 coefficient	 D	(cm2/s)	 and	 subject	 to	 uptake	 or	 binding	 mechanisms	 will	 diffuse	 in	 the	 brain	extracellular	space	according	to	the	following	equation:					
	where	the	position	of	the	diffusing	substance	over	time	is	given	by	(x,y,z)	(cm)	and	time	t	(s),	and	C	(nM)	is	the	concentration	of	diffusing	molecules.4,18	This	equation	factors	in	the	parameter	 f(C),	which	takes	 into	consideration	the	uptake	of	material	 from	the	ECS	into	cells	 (mM/s),	 and	 the	 local	 pressure	 release	 of	 molecules	 from	 a	 source,	 defined	 by	
Q(x,y,z,t)	 (mM/s).	 In	 the	 case	 of	 a	 targeted	 substance	 not	 taken	 up	 by	 the	 cell,	 the	parameter	 f(C)	 would	 be	 ‘0’,	 and	 only	 a	 parameter	 for	 the	 binding	 process	 would	 be	included.			
δt                                     α
=δC                             sD*    2 C  + (3)	
(4)	dC  =  D             −  f(C)  +  Q(x,y,z,t) 
dt       λ2                       α               α
2 C
dC  =  D             −  f(C)  +  Q(x,y,z,t) 
dt       λ2                       α               α
2 C
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	 In	summary,	a	number	of	 factors	must	be	considered	when	studying	diffusion	of	substances	 in	 the	 brain	 ECS.	 For	 untagged	 species,	 these	 factors	 are	 limited	 to	 those	properties	 that	 affect	 the	 effective	 diffusion	 of	 the	 substance	 through	 the	 ECS,	 such	 as	intrinsic	 properties	 of	 the	 species	 itself	 (size,	 shape,	 flexibility),	 tortuosity,	 and	 ECS	volume	 fraction.	 In	 addition	 to	 these	 parameters,	 for	 targeted	 species,	 we	 must	 also	consider	how	the	binding	of	the	species	to	target	sites	might	impede	the	diffusion	of	the	substance,	 which	may	 be	 beneficial	 in	minimizing	 non-specific	 cellular	 interactions	 yet	detrimental	to	the	effective	distribution	of	the	substance	throughout	the	tissue.	The	latter	case	is	a	phenomenon	known	as	the	“binding-site	barrier”.	
I.3		 The	 Effect	 of	 Ligand-Receptor	 Binding	 on	 Brain	 Tissue	 Distribution:	 The	
Binding-Site	Barrier	Designing	 diffusible	 and	 targeted	 molecules	 for	 binding	 to	 specific	 receptors	requires	that	the	affinity	of	the	molecule	for	the	receptor	be	within	a	desirable	range	and	ideally	 can	 be	 adjusted.	 Studies	 involving	 tumor	 cells	 have	 shown	 that	 antibody	penetration	through	the	tumor	tissue	can	be	significantly	retarded	for	antibodies	with	too	high	an	affinity	 for	 the	 tumor-expressed	receptor.20–22	Poor	distribution	of	 the	antibody	through	 the	 interstitium	 of	 the	 tumor	 cell	 would	 result	 in	 ineffective	 treatment.	Conversely,	too	low	affinity	of	an	antibody	(or	other	material)	for	the	receptor	results	in	poor	tumor	retention23	and,	 thus,	poor	targeting	selectivity	(tumor	over	healthy	tissue).	Further,	it	has	been	shown	that	expression	of	a	target	in	a	region	close	to	the	site	of	entry	poses	a	barrier	to	targeting	if	the	desired	region	is	farther	away	from	the	site(s)	of	entry.	These	 affinity-based	 limitations	 to	 effective	 targeting	 are	 collectively	 known	 as	 the	“binding-site	 barrier.”	 Based	 on	 published	 work	 with	 antibody	 tumor	 targeting,	
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predictions	 can	 be	 made	 about	 whether	 targeted	 (receptor-specific)	 antibodies	 will	experience	hindrances	to	effective	transport	through	the	tumor	interstitial	space	by	their	successful	 binding	 to	 the	 target	 near	 entry	 points.	 To	 our	 knowledge,	 the	 binding-site	barrier	has	not	been	demonstrated	in	the	context	of	molecular	targeting	to	cells	in	healthy	or	 injured	 brain	 tissue.	 The	 possibility	 of	 this	 effect	 is	 important	 to	 the	 design	 of	molecules	for	targeted	delivery	in	the	brain	as	both	high	affinity	and	non-specific	binding	of	 diffusible,	 targeted	 constructs	 to	 regions	 nearer	 the	 point	 of	 entry	 (such	 as	 regions	closer	 to	 penetrating	 blood	 vessels	 or	 paravascular	 spaces)	 may	 adversely	 affect	 their	distribution	to	desirable	targets	(neurons)	further	away.		
I.4		 Diffusion	versus	‘Bulk	Flow’:	Effect	on	Distribution	of	Molecules	in	the	Brain	Molecular	 diffusion	 is	 a	 very	 important	 but	 somewhat	 limited	 means	 through	which	 nutrients	 and	 therapeutics	 are	 distributed	 through	 the	 brain	 parenchyma,	especially	in	larger	brains	such	as	those	found	in	humans.	In	addition	to	diffusion,	a	more	deliberate	system	 is	 in	place	 to	 facilitate	 the	movement	of	 solutes	 throughout	 the	brain	parenchyma,	 particularly	 larger	 molecules	 such	 as	 proteins	 (e.g.,	 growth	 factors	 and	amyloid	 beta),	 which	 would	 otherwise	 experience	 great	 hindrance	 to	 movement	 and	clearance.	This	system	of	bulk	solute	movement	is	known	as	endogenous	bulk	flow.		Though	 the	mechanism	 and	 importance	 of	 endogenous	 bulk	 flow	 has	 long	 been	debated,11	 researchers	 have	 provided	 direct	 evidence	 for	 its	 existence.	 Cserr	 and	coworkers,	for	example,	have	shown	that	molecules	with	a	range	of	molecular	weights—900	and	4,000	MW	polyethylene	 glycols	 (PEGs)	 and	 radioiodinated	 albumin,	 and	4,000	MW	 PEG	 and	 70,000	 MW	 dextrans—are	 cleared	 from	 the	 brain	 parenchyma	 with	 the	
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same	 rate	 constant,13,24,25	 suggesting	 the	 existence	 of	 a	 clearance	 mechanism	 that	 is	independent	 of	 their	 diffusion	 coefficients.	 This	 bulk	 movement	 of	 solutes	 appears	restricted	 to	 the	 paravascular	 or	 Virchow-Robin	 spaces,11,25,26	 the	 cerebral	 spinal	 fluid	(CSF)-containing	 area	 surrounding	 blood	 vessels,	 and	 may	 be	 the	 primary	 mode	 of	removal	 of	 large	 molecules	 from	 the	 brain	 interstitial	 fluid.13	 Further,	 it	 has	 been	suggested	that	the	movement	of	solutes	from	the	CSF	of	the	paravascular	spaces	(PVS)	to	the	cisterna	magna	may	account	for	~10	–	20	%	of	cerebral	solute	loss.13		 The	CSF	that	constitutes	the	paravascular	space	originates	in	the	brain	and	spinal	cord18,27	(Figure	3-3,	A)	and		is	in	direct	contact	with	the	brain	interstitial	fluid	(ISF),	the	fluid	found	in	the	brain	extracellular	space.	Consequently,	the	CSF	serves	as	a	direct	point-of-entry	 through	 which	 nutrients	 and	 potential	 therapeutics	 can	 be	 introduced	 to	 the	brain.	 Bulk	 flow	 of	 solutes	 contained	 in	 the	 CSF	 is	 driven	 by	 arterial	 pulsations,	which	circulates	 fluid	 from	the	subarachnoid	space	of	 the	brain	 to	 the	PVS	 then	 into	 the	brain	ISF.	Small	molecular	weight	 tracers	such	as	horseradish	peroxidase26,28	and	Alexa	Fluor	594	 (759	Da),27	 and	 larger	 solutes	 such	 as	 dextrans29	 introduced	 to	 the	CSF	have	been	successfully	 distributed	 through	 brain	 tissue	 along	 paravascular	 spaces.	 Solutes	 were	shown	to	enter	brain	tissue	from	the	paravascular	spaces	surrounding	brain-penetrating	arteries	(Figure	3-3,	B).27	Solutes	then	leave	the	paravascular	spaces,	exchange	with	the	brain	 interstitial	 fluid	 of	 the	 brain	 extracellular	 space,	 then	 subsequently	 distribute	through	the	brain	tissue	(Figure	3-3,	C,	D).	Distributed	solutes	are	then	cleared	from	the	interstitial	 fluid	 back	 to	 the	 CSF	 along	 paravenous	 routes,	 that	 is	 alongside	 brain-penetrating	 veins	 (Figure	 3-3,	 B).27	 Further,	 bulk	 movement	 facilitated	 by	 this	“paravascular	 pump”	 can	 be	 enhanced	 by	 increased	 blood	 pressure	 and	 heart	 rate	 in	
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rats.30	 Taken	 together	 these	 data	 suggest	 that	 direct	 introduction	 of	 small	 to	medium-sized	molecules	 into	 the	 CSF	 coupled	with	 careful	manipulation	 of	 blood	 pressure	 and	heart	rate	may	be	an	effective	method	for	the	targeted	delivery	of	therapeutics	to	specific	cells	deep	in	brain	tissue.			Movement	 of	 solutes	 by	 bulk	 flow	 is	 size-independent;	 thus,	 small	 and	 large	
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Figure	 3-3.	 Paravascular	 and	 interstitial	 bulk	 flow	quickly	 distributes	molecules	 throughout	 the	
brain	 parenchyma.	 (A)	Tight	 junctions	between	endothelial	 cells	 (blue)	which	 line	blood	vessels	(red)	form	 the	 first	 layer	 of	 discriminant	 BBB.	 Astrocytic	 endfeet	 surround	 blood	 vessels,	 leaving	 an	approximately	20	nm	cleft	between	overlapping	endfeet	forming	an	additional	barrier	to	solute	entry	into	brain	 tissue.	 Solutes	 in	 the	 cerebral	 spinal	 fluid	 (CSF)	 can	 be	 distributed	 to	 the	 brain	 tissue	 from	 the	paravascular	 spaces	 (PVS)	 surrounding	 penetrating	 arteries	 and	 blood	 vessels	 (light	 pink).	 (B)	Paravascular	 bulk	 flow	 route.	 Para-arterial	 influx	 from	 subarachnoid	 CSF	 to	 ISF	 occurs	 along	 brain-penetrating	 arteries	 (red)	 whereas	 efflux/clearance	 of	 solutes	 from	 ISF	 to	 CSF	 occurs	 along	 brain-penetrating	 veins	 (blue).	 (C)	 The	 size-dependent	 distribution	 of	 fluorophores	 via	 “paravascular	 pump”	method	is	demonstrated	in	vivo:	Alexa	fluor	dye	A594	(red)	distributes	quickly	and	uniformly	throughout	brain	parenchyma	from	paravascular	spaces.	Distribution	of	the	macromolecule	TR-d3	(blue)	is	limited	to	the	 PVS	 and	 glial	 surfaces.	 Much	 larger	 FITC-dextran	 2000	 (green)	 is	 constrained	 solely	 to	 the	 PVS.		
Images	B-D	are	modified	from	Iliff	JJ	et	al	(2012),	Science	Translational	Medicine,	4(147):	1-12.27			
FITC-d2000 (molecular size, 2000 kD) entered the brain along para-
vascular spaces, was confined there, and did not enter the surrounding
interstitial space (Fig. 1, K and L). TR-d3 (molecular size, 3 kD) con-
centrated in the paravascular spaces but also entered the interstitium
both from the paravascular space (K and L) and from the pial surface
(M) (Fig. 1, K and L). TR-d3 was more widely distributed than FITC-
d2000, which is mainly localized paravascularly. The lower–molecular
weight A594 (molecular size, 759 daltons) moved quickly throughout
the brain interstitium, and only small amounts concentrated within
paravascular spaces (Fig. 1, H and J). Both A594 and TR-d3 moved
slowly and uniformly into the brain from the pial surface (Fig. 1, H, K,
and M). We then quantified parenchymal distribution of tracers of
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Fig. 1. Distribution of subarachnoid CSF into the
brain parenchyma. (A) The movement of ventric-
ular and subarachn id CSF into the brain paren-
chyma was evaluated after infusion of fluorescent
tracer into the lateral ventricle (LV) or cisterna
magna. (B to G) After 30 min of intraventricular
infusion, small– (A594; molecular size, 759 daltons;
red), moderate– (TR-d3; molecular size, 3 kD; blue),
and large–molecular weight (FITC-d2000; molecu-
lar size, 2000 kD; green) tracer movement into the
brain parenchyma was evaluated. 3V, third ventri-
cle; 4V, fourth ventricle. (D and G) Absence of tracer
in tissue remote from the periventricular space.
Insets, 4′,6-diamidino-2-phenylindole (DAPI) labeling
in the same fields of view. (H to J) Small–molecular
wei ht tracer pe meati n 30 min after intracisternal injection. Arrowh ads, low-level paravascular accumulation. (K to M) Distribution of intracisternally
injected TR-d3 (dark blue) and FITC-d2000 (green). Merge (light blue) indicates colocalization of TR-d3 and FITC-d2000. (N) Distributions of intracisternal
fluorescent tracers, quantified as a percentage of total brain volume (integrated slice areas). A594 occupied the greatest proportion of brain tissue. TR-d3
exhibited an intermediate distribution, whereas FITC-d2000 was highly restricted (n = 3, *P < 0.05). (O) Accumulation of radiotracer within the brain after
intracisternal injection of [3H]mannitol (molecular size, 182 daltons) or [3H]dextran-10 (molecular size, 10 kD). Compared to [3H]mannitol, [3H]dextran-10
accumulation in the brain was significantly slower (n = 6 per time point, *P < 0.0001). Scale bars, 100 mm.
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compartment recirculates through the brain parenchyma. After intra-
cisternal 125I-amyloid b1–40 injection, brain
125I-amyloid b1–40 levels
increased in a manner comparable to [3H]dextran-10 (Fig. 6E, com-
pare to Fig. 1O). In the Aqp4-null mouse, bulk influx of 125I-amyloid
b1–40 was significantly reduced compared to wild types (Fig. 6E). These
data suggest that although interstitial soluble Ab is cleared along
the gliovascular pathway, a portion of
Ab within the CSF compartment may
recirculate through the brain along this
same route.
DISCUSSION
We have identified a brain-wide pathway
for fluid transport in mice, which in-
cludes the para-arterial influx of sub-
arachnoid CSF into the brain interstitium,
followed by the clearance of ISF along
large-caliber draining veins. Interstitial
bulk flow between these influx and efflux
pathways depends upon trans-astrocytic
water movement, and the continuous move-
ment of fluid through this system is a
critical contributor to the clearance of in-
terstitial solutes, likely including soluble
Ab1–40, from the brain. In light of its depen-
dence on glial water flux, and its subser-
vience of a lymphatic function in interstitial
solute clearance, we propose that this sys-
tem be called the “glymphatic” pathway
(Fig. 5B and fig. S9).
The relationship between the CSF
compartment and the peripheral lym-
phatics is well established (8). In mam-
mals, ~50% of radiolabeled albumin
injected into the CSF drains to the cervi-
cal lymphatics via the cribriform plate,
whereas the remainder is cleared to the
bloodstream via arachnoid granulations
of the dural sinuses (22–24). These recog-
nized patterns of drainage initially led to
the concept that CSF serves a “lymphatic”
function through its exchange with brain
ISF along paravascular spaces (6, 25).
Consistent with our findings reported here,
studies in the rat demonstrated that as
much as 75% of tracer injected into the
brain interstitium was cleared to the sub-
arachnoid CSF, accounting for about 11%
of total CSF production (26). Our identi-
fication of paravenous pathways, particu-
larly those surrounding the medial internal
cerebral and caudal rhinal veins, as the
primary route for clearance is in contrast
to some studies identifying para-arterial
sheaths as pathways for tracer clearance
(26, 27). We surmise that this para-arterial
labeling after intraparenchymal injections is largely an artifact of high
local intraparenchymal pressure from the injection and does not re-
flect the natural pathway for solute efflux. We observed that with in-
traparenchymal injections, para-arterial spaces accumulated tracer
close to the injection site. If observations are limited to these sites,
then it might mistakenly be concluded that tracer efflux is occurring
A
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Fig. 5. The gly phatic syste su ports interstitial solute and fluid clearance from the brain. (A) To eval-
uate the role of th clearance of interstitial solutes, we measured the elimination of intrastriate [3H]mannitol
from the brain (for details, see fig. S8A). Over the first 2 hours after injection, the clearance of intrastriate
[3H]mannitol from Aqp4-null mouse brains was significantly reduced (*P < 0.01, n = 4 per time point)
compared to WT controls. (B) Schematic depiction of the glymphatic pathway. In this brain-wide pathway,
CSF enters th brain alo g para-arterial routes, whereas ISF is cleared from the brain along paravenous
routes. Convective bulk ISF flow between these influx and clearance routes is facilitated by AQP4-
dependent astroglial water flux and drives the clearance of interstitial solutes and fluid from the brain
parenchyma. From h re, solutes and fluid may be dispersed into the subarachnoid CSF, enter the
bloodstream across the postcapillary vasculature, or follow the walls of the draining veins to reach the
cervical lymphatics.
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FITC-d2000 (molecular size, 2000 kD) entered the brain along para-
vascular spaces, was confined there, and did not enter the surrounding
interstitial space (Fig. 1, K and L). TR-d3 (molecular size, 3 kD) con-
centrated in the paravascular spaces but also entered the interstitium
both from the paravascular space (K and L) and from the pial surface
(M) (Fig. 1, K and L). TR-d3 was more widely distributed than FITC-
d2000, which is mainly localized paravascularly. The lower–molecular
weight A594 (molecular size, 759 daltons) moved quickly throughout
the brain interstitium, and only small amounts concentrated within
paravascular spaces (Fig. 1, H and J). Both A594 and TR-d3 moved
slowly and uniformly into the brain from the pial surface (Fig. 1, H, K,
and M). We then quantified parenchymal distribution of tracers of
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Fig. 1. Distribution of subarachnoid CSF into the
brain parenchyma. (A) The movement of ventric-
ular and subarachnoid CSF into the brain paren-
chyma was evaluated after infusion of fluorescent
tracer into the lateral ventricle (LV) or cisterna
magna. (B to G) After 30 min of intraventricular
infusion, small– (A594; molecular size, 759 daltons;
red), moderate– (TR-d3; molecular size, 3 kD; blue),
and large–molecular weight (FITC-d2000; molecu-
lar size, 2000 kD; green) tracer movement into the
brain parenchyma was evaluated. 3V, third ventri-
cle; 4V, fourth ventricle. (D and G) Absence of tracer
in tissue remote from the periventricular space.
Insets, 4′,6-diamidino-2-phenylindole (DAPI) labeling
in the same fields of view. (H to J) Small–molecular
weight tracer permeation 30 min after intracisternal injection. Arrowheads, low-level paravascular accumulation. (K to M) Distribution of intracistern lly
injected TR-d3 (dark blue) and FITC-d2000 (green). Merge (light blue) indicates colocalization of TR-d3 and FITC-d2000. (N) Distributions of intracisternal
fluorescent tracers, quantified as a percentage of total brain volume (integrated slice areas). A594 occupied the greatest proportion of brain tissue. TR-d3
exhibited an intermediate distribution, whereas FITC-d2000 was highly restricted (n = 3, *P < 0.05). (O) Accumulation of radiotracer within the rain after
intracisternal injection of [3H]mannitol (molecular size, 182 daltons) or [3H]dextran-10 (molecular size, 10 kD). Compared to [3H]mannitol, [3H]dextran-10
accumulation in the brain was significantly slower (n = 6 per time point, *P < 0.0001). Scale bars, 100 mm.
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	 Small	 and	 macromolecular	 tropane-tagged	 fluorescent	 probes	 were	 studied	 in	living	mouse	brain	tissue	to	evaluate	the	effect	of	size,	affinity,	and	molecular	construction	on	 targeting	 to	 the	 dopamine	 transporter	 (DAT).	 Untagged	 analogous	 constructs	 were	also	tested	to	serve	as	controls.	 	The	structure	of	 the	materials	evaluated	 is	provided	in	
Table	 3-1;	 the	 synthesis	 and	 spectral	 characterization	 of	 these	 probes	 is	 provided	 in	Chapter	2.	












































































































































































II.1		 Local	Injection	of	Tagged	QD	in	Barrel	Cortex	in	vivo.			 In	an	effort	to	find	a	suitable	platform	for	targeted	delivery	to	dopaminergic	cells	in	the	living	mouse	brain,	we	evaluated	a	construct	that	would	be	both	amenable	to	multi-functionalization	and	effectively	penetrate	brain	tissue	to	specifically	label	dopaminergic	axons.	 A	 variety	 of	 commercially	 available	 quantum	 dots	 are	 amenable	 to	functionalization	 and	 are	 well-reputed	 for	 use	 in	 fluorescence	 microscopy	 and	 other	biological	applications.33	Thus,	we	chose	commercially	available,	streptavidin-conjugated	QD605®	 (ThermoFisher)	 as	 an	 initial	 candidate	 for	 our	 delivery	 platform.	 We	 used	 a	bifunctional	 analogue	 of	 our	 DAT-binding	 ligand	 (see	 Chapter	 2	 for	 preparation	 and	Chapter	1	 for	 target	rationale)	 that	was	PEGylated	on	one	end	to	allow	flexibility	at	 the	DAT-binding	site,	and	biotinylated	at	the	other	end	to	allow	binding	to	the	streptavidin-quantum	 dot	 conjugates	 (Table	 3-1,	 Tagged	 QD).	 According	 to	 Invitrogen	 (now	ThermoFisher),	an	average	of	5-10	streptavidin	units	are	present	on	each	quantum	dot.	We	did	not,	 however,	 independently	 confirm	 this.	 	Assuming	an	 average	minimum	of	5	streptavidin	proteins	per	quantum	dot,	a	5-to-1	molar	ratio	of	DATL-PEG5000-Biotin	to	SA-QD	was	 used	 for	 an	 estimated	 average	 of	 5	 DATL-PEG5000-Biotins	 per	 SA-QD,	 ensuring	that	 no	 excess,	 unbound	 (and	 undetectable)	 DATL-PEG5000-Biotin	 would	 be	 present	 to	compete	with	binding	of	the	Tagged	QD	construct	to	DAT.	It	is	important	to	note	that	each	streptavidin	protein	is	capable	of	binding	up	to	4	biotinylated	ligands,	so	a	minimum	of	5	
DATL:	 Dopamine	 transporter	 (DAT)	 ligand,	 the	 tropane	 ligand	 featured	 in	 ECN127	 (outlined	 in	 green	box);	 RRX:	 Rhodamine	 red-X	 fluorophore;	 PEG:	 polyethylene	 glycol,	 different	molecular	 weights;	 DNB:	tetrameric	neutravidin	protein	(‘N’)	bound	to	two	biotin-PEG5000-conjugated	DAT	ligands	(‘D’)	and	two	biotinylated	Alexa	Fluor594	fluorophores	separated	by	a	short	linker	(‘B’);	DumNB:	similar	to	DNB	except	bound	to	two	biotin-PEG5000	units	without	a	tropane	tag;	SA-QD:	Quantum	Dot605®	with	an	average	of	5-10	streptavidin	units	on	its	surface.					
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strepavidin	 proteins	 per	 quantum	 dot	 would	 allow	 the	 binding	 of	 at	 least	 20	 DATL-PEG5000-Biotin	(20:1	DATL-PEG5000-Biotin:SA-QD,	molar	ratio).			After	confirming	the	binding	of	the	Tagged	QD	construct	to	hDAT	in	cultured	EM4	(HEK)	 cells	 stably	 expressing	 the	 human	 dopamine	 transporter,	 and	 having	 confirmed	that	 the	 fluorescent	 DAT	 ligand	 ECN127	 also	 binds	 with	 high	 affinity	 to	 the	norepinephrine	transporter	(NET)	(Chapter	2),	we	sought	to	test	whether	this	construct	could	selectively	label	noradrenergic	axons	in	vivo,	thus	testing	the	viability	of	the	SA-QD	as	 a	 potential	 platform	 for	 targeted	 delivery	 in	 living	 brain	 tissue.	 As	 such,	 Tagged	QD	(~150	nL,	2.5	μM	in	DATL,	Figure	3-4,	A)	was	injected	locally	into	layer	1	of	the	barrel	cortex	 through	 an	 open	 cranial	 window	 in	 an	 anesthetized	 TH-GFP	 transgenic	 control	mouse,	 and	 imaged	using	 two-photon	microscopy	 (Figure	 3-4,	 B,	 in	 collaboration	with	Dr.	 Matthew	 Dunn).	 The	 barrel	 cortex	 was	 chosen	 because	 it	 is	 innervated	 by	noradrenergic	 projections	 from	 the	 locus	 coeruleus	 (LC)34	 and	 may	 serve	 as	 a	 useful	experimental	 system	 for	 studying	 in	 vivo	 targeting	 properties	 of	 our	 tropane-tagged	constructs.	In	this	TH-GFP	mouse	model,	green	fluorescent	protein	(GFP)	is	expressed	in	dopaminergic	and	noradrenergic	neurons	under	the	control	of	the	promoter	for	tyrosine	hydroxylase	 (TH)	 and,	 as	 such,	 is	 used	 as	 a	 positive	 marker	 for	 these	 neurons.	 Two-photon	microscopy	 revealed	 high	 background	 fluorescence	 near	 the	 injection	 site	 area,	suggesting	 that	 the	 probe	was	mostly	 localized	 to	 the	 region	 surrounding	 the	 injection	site	and	did	not	 sufficiently	penetrate	 the	brain	 tissue	 (Figure	 3-4,	 C).	However,	 at	 the	outer	 edge	 of	 the	 injection	 site,	 which	 had	 less	 background	 staining,	 anatomical	coincidence	between	Tagged	QD	and	TH-GFP	can	be	seen,	suggesting	that	Tagged	QD	can	label	noradrenergic	neurons	(Figure	3-4,	C,	arrows).		
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These	 results	 suggest	 that	 though	 SA-QD	 quantum	 dots	 are	 useful	 for	 many	biological	applications,	they	are	ill-suited	for	use	in	vivo	imaging	of	brain	tissue.	In	spite	of	












Figure	3-4:	Local	injection	of	Tagged	QD	(DATL-PEG5000-BIO/SA-QD)	in	the	living	mouse	brain.	(A)	A	simplified	 depiction	 of	 the	 Tagged	 QD	 construct.	 (B)	 The	 mouse	 barrel	 cortex:	 schematic	 depiction	 of	microanatomical	segments	of	somatosensory	cortex,	called	barrels,	in	the	(x,	y)	plane.	Image	adapted	from	http://www2.psy.unsw.edu.au/users/earabzadeh/Research.html.	(C)	Layer	1	refers	to	cortical	column	1,	the	 first	100	μm	below	the	pial	surface.	 Image	adapted	from	Chen-Bee	CH	et	al,	Front.	Neural	Circuits,	27	
November	2012. (D)	A	solution	of	2.5	uM	(in	DATL)	Tagged	QD	(~150	nL)	was	injected	into	layer	1	of	the	Barrel	Cortex.	Left	(red):	Tagged	SA-QD,	middle	(green):	TH-GFP,	right:	Merged.	In	vivo	image	courtesy	of	
Matthew	R.	Dunn.			
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Though	these	in	vivo	experiments	did	not	yield	the	expected	results,	they	did	lead	us	to	ask	new	questions	about	the	diffusion	and	subsequent	binding	of	(macro)molecules	in	 brain	 tissue.	 We,	 thus,	 sought	 to	 understand	 1)	 what	 factors	 govern	 the	 successful	tissue-penetration	 of	 molecules	 in	 the	 brain,	 2)	 how	 can	 targeting	 (specific	 binding	 to	chosen	 cell	 types)	 be	 affected	by	 these	 factors	 and	3)	what	 contributing	 factors	 ensure	that	targeted	molecules	are	efficiently	cleared	from	the	brain	parenchyma	if	unbound	or	after	 reaching	 the	 specific	 target	 and	 eliciting	 the	 desired	 results.	 To	 answer	 these	questions,	we	designed	small	and	macromolecular	probes	bearing	the	tropane	moiety	to	target	the	dopamine	transporter	(DAT)	(Table	3-1).		We	chose	dopaminergic	axons	in	the	mouse	 dorsal	 striatum	 as	 our	 model	 system	 as	 changes	 in	 levels	 of	 dopaminergic	innervation	are	found	in	pathologies	such	as	ADHD,	Parkinson’s	disease,	depression,	and	addiction;	the	striatum	is	heavily	 innervated	with	dopaminergic	projections;	and	DAT	is	selectively	expressed	on	dopaminergic	axons.	We	then	evaluated	the	diffusion	behaviors	of	these	probes	in	the	brain	tissue	in	the	context	of	targeting	to	dopaminergic	axons.		
II.2		 Co-localization	of	ECN127	with	DAT	Substrate	FFN102	Binding	of	the	tropane-conjugated	ligands	ECN127,	PSN102,	DNB,	and	Tagged	QD	(Table	1)	 to	 the	dopamine	 transporter	was	 first	 confirmed	 in	 cultured	EM4	cells	 stably	expressing	hDAT	(hDAT-EM4	cells;	see	Chapter	2).	ECN127,	PSN102,	and	DNB	were	also	tested	for	potency	of	hDAT	uptake	inhibition	(IC50)	and	were	determined	to	be	76.0	±	12.5	nM,	2.18	±	0.60	μM,	 and	737	±	208	 nM,	 respectively	 (Mean	±	SEM;	Chapter	2).	Having	confirmed	the	activity	of	these	probes	at	DAT	in	cultured	cells,	we	sought	to	study	their	binding	and	diffusion	properties	in	mouse	brain	tissue.		
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Small	molecule	ECN127	was	applied	 to	acute	 slice	preparations	and	a	 string-like	staining	pattern	was	observed.	To	verify	that	this	probe	was	labeling	dopaminergic	axons	in	the	striatum,	we	performed	co-localization	experiments	with	FFN102	(Figure	3-5,	A).	FFN102,	 a	 fluorescent	 false	 neurotransmitter	 developed	 in	 our	 laboratory,	 is	 a	 DAT-selective	 substrate	 that	was	 previously	 reported35	 to	 have	 high	 anatomical	 coincidence	with	 tyrosine	hydroxylase	 expression	 in	 the	TH-GFP	 transgenic	mouse	model.	Again,	 in	this	 model,	 GFP	 is	 expressed	 in	 dopaminergic	 and	 noradrenergic	 neurons	 under	 the	control	of	the	promoter	for	tyrosine	hydroxylase	and,	as	such,	is	used	as	a	positive	marker	for	 these	 neurons.	 Therefore,	 co-localizing	 the	 staining	 pattern	 of	 our	 targeted	 probes	with	 that	 of	 FFN102	 would	 confirm	 that	 our	 probes	 were	 selectively	 labeling	dopaminergic	axons.	Acute	striatal	slices	from	wild-type	(WT)	mice	were	treated	with	10	μM	FFN102	for	30	minutes	then	with	20	nM	ECN127	for	15	minutes.	Experimental	results	obtained	by	Jihang	Wang	showed	that	73.2	±	2.5	%	(Mean	±	SEM)	of	FFN	puncta	pixels	are	located	on	ECN127	‘strings’	(Figure	3-5,	B),	confirming	ECN127	as	an	excellent	label	for	dopaminergic	 projections	 in	 the	 dorsal	 striatum	 of	mouse	 brain.	 The	 string-like	 versus	punctate	 staining	 pattern	 observed	 for	 ECN127	 and	 FFN102,	 respectively,	 is	 consistent	with	the	differential	mechanisms	of	these	two	probes.	FFN102	is	a	DAT	substrate	and	is	concentrated	 in	 vesicles	 by	 action	 of	 vesicular	 monoamine	 transporter	 2	 (VMAT2)	whereas	 ECN127	 is	 a	 DAT	 inhibitor	 and	 binds	 to	 DAT	 expressed	 at	 the	 surface	 of	dopaminergic	axons.	ECN127	specificity	for	dopaminergic	neurons	was	further	confirmed	by	 anatomical	 coincidence	 with	 a	 TH-GFP	 control	 mouse	 (not	 shown).	 Briefly,	 ECN127	was	 applied	 to	 acute	 slice	 preparations	 of	 a	 TH-GFP	 control	 mouse	 and	 a	 string-like	staining	 pattern	 was	 observed	 in	 both	 the	 ECN127	 and	 the	 TH-GFP	 channels.	 Co-
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localization	of	the	ECN127	staining	pattern	(pixels)	with	that	of	TH-GFP	provided	further	confirmation	of	ECN127	labeling	of	dopaminergic	axons.					These	results	suggest	that	the	tropane	ligand	used	for	the	synthesis	of	other	DAT-specific	 (macro)molecular	 probes	 can	 be	 used	 as	 a	 targeting	 ligand	 for	 dopaminergic	neurons	in	areas	of	high	dopaminergic	innervation.		
II.3		 Two-photon	Imaging	of	DAT-targeted	and	Non-targeted	Small	Molecule	and	
PEGylated	Macromolecular	Probes	in	Dorsal	Striatum	of	Mouse	Brain.		The	diffusion	and	binding	characteristics	of	targeted	probes	were	studied	in	slices	of	 dorsal	 striatum	 using	 two-photon	 microscopy	 (Figure	 3-6).	 Analogous	 constructs	













Figure	3-5:	ECN127	co-localizes	with	FFN102	and	TH-GFP	in	acute	mouse	brain	slices.	(A)	Structure	of	 FFN102,	 TFA	 salt.	 (B)	 ECN127	 (shown	 in	 red)	 co-localizes	 with	 FFN102	 (shown	 in	 green)	 in	 dorsal	striatum	of	acute	mouse	brain	slices.	Overlay	of	the	two	channels	(right	panel)	shows	good	co-localization	(73.2	±	2.5%)	of	ECN127	pixels	with	FFN102	pixels	(when	analyzed	as	previously	reported35.	FFN102	is	shown	 in	 pseudogreen	 color,	 ECN127	 is	 shown	 in	 red.	 Yellow	 indicates	 co-localization.	 Each	 image	represents	a	30	min	pretreatment	of	slice	with	FFN102	followed	by	a	15-minute	treatment	with	ECN127.	Slices	were	washed	with	artificial	cerebral	spinal	fluid	(ACSF)	for	several	minutes	before	imaging.	Images	
are	from	collaboration	with	Jihang	Wang.	
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the	course	of	the	experiment,	demonstrating	the	high	affinity	of	the	small	molecule	for	the	receptor.	 In	 contrast,	 the	 fluorescence	 signal	 for	 the	 non-targeted	 small	 molecule	fluorophore	 (OH-RRX)	 quickly	 diminished	 seconds	 after	 its	 ejection	 onto	 tissue	 (38.5	seconds	 post	 ejection,	 images	 not	 shown),	 demonstrating	 its	 fast	 diffusion	 to	 and	clearance	 from	 the	 tissue.	Compared	 to	 the	 targeted	DATL-RRX,	 the	 fluorescence	 signal	for	non-targeted	OH-RRX	returns	to	background	signal	levels	after	~2	minutes	(Figure	3-








































































eTSeries	#		 	1	 	 		 10	 	 						54		 	 					 	75			 -3.83																		*																		1.9	 	 											24.6	 							 					43.4	 		(min)		
Figure	3-7.	Diffusion	of	DAT	 targeted	and	non-targeted	small	molecule	and	analogous	PEGylated	
polymer	in	brain	tissue.	Fluorescent	materials	were	pressure	ejected	(2	x	50	.6	nL	ejected	at	46	nL/sec)	onto	the	surface	of	300	μm-thick	acute	slices	in	the	dorsal	striatal	region	of	the	tissue.	Images	shown	are	representative	 for	 each	 probe	 at	 a	 depth	 of	 15	 μm	 from	 surface.	 (A)	 Tropane-tagged	 small	 molecule	ECN127	quickly	(1.9	min)	 labels	dopaminergic	axons	in	ex	vivo	brain	tissue	[200	nM	ECN127	(N	=	2,	n	=	3)]	 while	 non-targeted	 small	 molecule	 control	 does	 not	 (B)	 [200	 nM	 OH-RRX	 (N	 =	 2,	 n	 =	 2)],	 quickly	diffusing	 through	 the	 tissue.	 (C)	 Tropane-tagged	 PEGylated	 polymer	 PSN102	 also	 labels	 dopaminergic	axons	 but	 requires	more	 time	 (~24	min	 post	 ejection)	 to	 do	 so	 [5	 μM	 PSN102	 (N	 =	 2,	 n	 =	 3)].	 (D)	 In	contrast,	the	images	show	that	non-targeted	PEGylated	polymer	DumPSN	quickly	diffuses	to	the	tissue	(in	1.9	min)	and	is	retained	throughout	the	experiment	but	does	not	label	dopaminergic	axons	[5	uM	DumPSN	(N	=	3,	n	=	3)].	N	=	total	number	of	animals,	n	=	total	number	of	brain	slices	used.	Imaged	at	ex:	870	nm	em:	555	–	605	nm.	60x	magnification,	4x	optical	zoom.		(Scale	bars:	10	μm.)		
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Quantitative	 analyses	 of	 the	 tissue	 distribution	 of	 these	 probes	 are	 shown	 in	
Figure	3-8.	To	generate	these	plots,	the	fluorescence	signal	at	each	depth	was	normalized	to	 the	 initial	 fluorescence	 signal	 at	 the	 slice	 surface	 (z	 =	 0	 μm)	 at	 the	 first	 time	 point	collected	after	probe	ejection.	This	fluorescence	signal	was	assumed	to	be	the	maximum	amount	 of	 probe	 applied	 to	 the	 slice.	 At	 a	 depth	 of	 15	 μm	 from	 the	 surface,	 the	fluorescence	 signal	 for	 OH-RRX	 is	 reduced	 from	 0.62	 at	 t	 =	 0.1	minutes	 (the	 first	 time	point	collected	after	ejection)	to	0.40	at	t	=	1.3	minutes,	a	~64%	reduction	in	just	over	one	minute	(Figure	3-8,	C).	In	contrast,	the	initial	fluorescence	signal	for	DumPSN	is	reduced	by	~60%	after	43	minutes	(Figure	3-8,	D).	The	diffusion	pattern	of	untagged	OH-RRX	and	DumPSN	in	the	dorsal	striatum	show	diminishing	concentration	with	time	(Figure	3-8,	C	
and	 D),	 as	 would	 be	 expected	 for	 diffusion	 of	 untagged	 substances.	 Their	 diffusion	patterns	 are	 similar	 in	 appearance	 to	 substances	 whose	 diffusion	 (rate	 of	 change	 in	concentration	over	time)	can	be	modeled	using	a	δ-function	source	density	equation	(5),18		
	where	D*	is	the	apparent	diffusion	coefficient,	r	is	the	distance	from	the	point	source,	and	
N	is	the	number	of	moles	of	substance	introduced	to	the	slice.	The	effect	of	size	on	rates	of	brain	 tissue	diffusion	can	be	seen	by	comparison	of	 the	rates	at	which	 the	 fluorescence	signals	 of	 OH-RRX	 and	 DumPSN	 diminish.	 This	 size-effect	 would	 be	 reflected	 in	 their	respective	apparent	diffusion	coefficients	D*,	which	could	be	determined	if	the	data	were	fit	to	equation	(5).		
δt          r        δr2             r2
=δC       D*  δ




A	similar	size-effect	on	apparent	rate	of	diffusion	through	tissue	is	observed	for	the	tropane-tagged	 molecules	 ECN127	 and	 PSN102	 (Figure	 3-8,	 A	 and	 B,	 respectively).	Though	ECN127	more	quickly	diffuses	to	distances	r	from	the	point	source,	at	a	depth	of	15	μm,	PSN102	is	able	to	reach	a	similar	total	fluorescence	signal	(FTot/F0*	=	1.0)	at	43.4	
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DATL-RRX	 	 	 						OH-RRX	
	(ECN127)	
DATL-PEG5000-RRX	 	 DumL-PEG5000-RRX	
									(PSN102)	 	 	 										(DUMPSN)	
Figure	3-8.	Tissue	penetration	of	DAT	targeted	and	non-targeted	(”dummy”)	fluorescent	probes	in	
dorsal	striatum.	A	2x50.6	nL	volume	containing	a	solution	of	molecules	was	ejected	onto	tissue	at	time	t	=	0*	minutes,	after	collecting	background	images	for	3.83	minutes.	For	panels	A	–	D,	 the	change	 in	total	fluorescence	signal	at	each	distance	from	the	surface	(x-axis)	at	the	indicated	time	points	was	normalized	to	 the	 initial	 fluorescence	signal	 at	 the	 slice	 surface	 (0	μm)	at	 the	 time	 just	 after	probe	ejection	(t	=	0.1	minutes*).	The	fluorescence	signal	(apparent	concentration)	of	tagged	small	molecule	DATL-RRX	(A)	and	its	polymeric	 analogue	DATL-PEG3400-RRX	(B)	 increase	with	 time	even	at	depths	 farther	 from	the	tissue	surface,	 while	 the	 fluorescence	 signal	 of	 the	 corresponding	 untagged	 analogues	 RRX	 (C)	 and	 DumL-PEG3400-RRX	 (D)	 decrease	 with	 time.	 Plotting	 the	 area	 under	 the	 curve	 over	 time	 demonstrates	 the	tendency	for	each	probe	to	be	 retained	or	cleared	 from	the	tissue	 in	the	45	min	time	course.	(E)	DATL-RRX	is	retained	in	tissue	and	increases	with	time	while	OH-RRX	quickly	diffuses	away.	Similarly,	(F)	the	concentration	 of	 DATL-PEG3400-RRX	 also	 appears	 to	 increase	 with	 time	 while	 DumL-PEG3400-RRX	 is	cleared	from	tissue,	though	more	slowly	than	RRX.	Note	different	axes	on	each	graph.	
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minutes	 as	 ECN127	 (FTot/F0*	 =	 1.1)	 reaches	 at	 1.9	 minutes	 (Figures	 3-8,	 A,	 B).	 At	 a	distance	 of	 45	 μm	 from	 the	 surface,	 the	 ECN127	 fluorescence	 signal	 increased	significantly	 from	0.24	 at	 14.7	minutes	 to	 0.32	 at	 43.4	minutes	 (*P	 =	 0.02;	 paired	 two-tailed	 t	 test).	 It	 is	 estimated	 that	 the	 distance	 between	 a	 blood	 vessel	 and	 the	 nearest	parenchymal	cell	is	~50	μm	in	the	most	innervated	regions.18	Thus,	the	ability	of	a	small	quantity	 (200	 nM,	 101.2	 nL)	 of	 ECN127	 to	 diffuse	 to	 and	 target	 DAergic	 axons	 at	 a	distance	 of	 ~50	 μm	 within	 this	 experimental	 time	 frame	 is	 physiologically	 relevant.	PSN102,	on	the	other	hand,	did	not	significantly	reach	distances	past	25	μm	from	tissue	surface	within	this	experimental	time	frame	(Figure	3-8,	B),	demonstrating	the	effect	of	the	3400	MW	PEG	chain	on	slowing	the	rate	of	diffusion	of	the	tagged	fluorescent	probe.	It	is	 possible	 that	 PSN102	 would	 reach	 larger	 distances	 given	 enough	 time,	 though	 the	length	of	 time	 required	 for	 this	 volume	and	 concentration	of	 probe	 to	 reach	 significant	concentrations	at	the	physiologically	relevant	distance	of	50	μm	was	not	evaluated.		In	addition	to	size	effects	on	molecular	diffusion,	an	important	goal	for	this	project	is	 to	 understand	 how	 selective	 targeting	 effects	 the	 diffusion	 and	 tissue	 distribution	 of	similarly	and	differentially	sized	probes	over	time.	To	understand	this	effect,	we	plotted	the	area	under	the	curves	of	the	tissue	distribution	plots	(Figure	3-8,	A-D)	for	each	probe	at	 the	 indicated	 time	 points	 (Figure	 3-8,	 E,	 F).	 ECN127	 is	 retained	 in	 tissue	 to	 a	significantly	 greater	 extent	 than	 untagged	 OH-RRX,	 which	 quickly	 diffuses	 from	 tissue	(Figure	 3-8,	 E).	 Similarly,	 tropane	 tagged	 PSN102	 is	 retained	 in	 tissue	while	 untagged	DumPSN	is	cleared,	though	DumPSN	is	cleared	at	a	much	slower	rate	than	OH-RRX.	The	slow	rate	at	which	the	fluorescence	signal	changes	for	PSN102	at	15	μm	below	the	slice	surface	 (Figure	 3-8,	 E,	 F,	 first	 three	 time	points)	 suggests	 that	not	only	 is	 its	diffusion	
	 119	
size-limited	 relative	 to	 ECN127,	 but	 its	 tissue	 penetration	 relative	 to	 DumPSN	 is	 also	hindered	by	 its	affinity	 for	DAT,	suggesting	a	binding-site	barrier	effect	(as	described	 in	Chapter	3,	section	I.3).	This	effect	does	not	appear	to	exist	with	ECN127	suggesting	that	its	high	affinity	for	DAT	is	overcome	by	its	fast	diffusion	kinetics;	in	other	words,	ECN127	targeting	 is	 ‘diffusion	 dominant’.36	 It	 appears,	 however,	 that	 targeting	 of	 PSN102	 is	governed	by	both	its	apparent	diffusion	coefficient	D*	and	its	moderate	DAT	affinity	(Ki,	or	 kon/koff,	 where	 kon	 and	 koff	 are	 the	 binding	 and	 dissociation	 rate	 constants	 at	 DAT,	respectively;	see	Figure	 2-1).	Thus,	addition	of	 the	PEG	chain	appears	 to	both	slow	the	diffusion	 of	 the	 tropane	 tag	 and	 render	 it	 susceptible	 to	 the	 binding-site	 barrier	 effect.	This	has	profound	implications	for	the	design	of	polymeric	materials	for	cell	type-specific	targeted	delivery	in	brain	tissue.	
II.4		 Two-photon	Imaging	of	DAT-targeted	and	Non-targeted	Neutravidin	Protein	
Polymer	and	Quantum	Dot	in	Dorsal	Striatum	of	Mouse	Brain.		The	 binding	 characteristics	 of	 the	 relatively	 large	 DATL-tagged	 and	 -untagged	neutravidin	protein	polymers	(DNB	and	DumNB,	respectively)	and	tagged	and	untagged	quantum	 dots	 (tagged	 QD	 and	 untagged	 QD,	 respectively)	 (Table	 1)	 were	 similarly	studied	 in	 dorsal	 striatum	 using	 two-photon	microscopy	 and	 pressure	 ejection	 using	 a	NanojectII.	Representative	 image	 sequences	of	 tagged	and	untagged	protein	and	 tagged	and	untagged	quantum	dot	at	15	μm	below	slice	surface	are	shown	in	Figures	3-9	and	3-
10,	respectively.	In	 spite	 of	 its	 relatively	 large	 size	 (~80,000	 MW,	 dH	 ~	 7-12	 nm),	 the	 protein	polymer	DNB	penetrated	the	brain	tissue	and	successfully	labeled	dopaminergic	axons	15	
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μm	below	the	slice	surface	(Figure	3-9,	A).	In	contrast,	the	non-targeted	protein	polymer	DumNB,	 was	 not	 retained	 in	 the	 tissue	 and	 was	 successfully	 cleared	 with	 minimal	background	 staining	 (Figure	 3-9,	 B).	 This	 is	 also	 in	 contrast	 to	 the	 high	 nonspecific	staining	 observed	 with	 untagged	 PEG	 polymer	 DumPSN.	 These	 data	 show	 that	 a	 large	(~12	nm),	relatively	rigid	protein	polymer	can	be	successfully	targeted	to	specific	cells	in	living	brain	tissue.		On	 the	 other	 hand,	 the	 much	 larger	 (~35	 nm)	 tagged	 and	 untagged	 QDs	 were	unsuccessful	at	penetrating	the	tissue	even	to	a	depth	of	15	μm	below	the	surface	(Figure	
3-10	 A,	 B).	 Tagged	 QD,	 however,	 was	 able	 to	 label	 dopaminergic	 axons	 on	 the	 slice	
Figure	 3-9.	 Diffusion	 of	 DAT	 targeted	 and	 non-targeted	 neutravidin	 protein	 polymer	 in	 brain	
tissue.	Fluorescent	materials	were	pressure	ejected	(2	x	50.6	nL	ejected	at	46	nL/sec)	onto	the	surface	of	300	 μm-thick	acute	 slices	 in	 the	dorsal	 striatal	brain	 region.	 Images	 shown	are	 representative	 for	 each	probe	at	 a	depth	of	15	μm	 from	surface.	A	 series	of	background	 images	were	acquired	before	pressure	ejection	 of	 fluorescent	 materials,	 which	 occurred	 at	 the	 time	 indicated	 by	 the	 asterisk,	 followed	 by	continuous	imaging	of	the	volume	until	the	end	of	the	experiment	(43.4	minutes	post	ejection).	(A)	10	μM	DNB	 (10	 μM	 DATL-PEG5000-Biotin:	 5	 μM	 Neutravidin:	 10	 μM	 BiocytinAlexaFluor594,	 2:1:2	molar	 ratio	D:N:B),	labels	dopaminergic	axons	~24	minutes	post	ejection	onto	slice	surface	(N	=	3,	n	=	4).	 	(B)	10	μM	DumNB,	(10	μM	DumL-PEG5000-Biotin,	2:1:2	molar	ratio	Dum:N:B)	 is	does	not	 label	dopaminergic	axons	and	is	sufficiently	cleared	from	tissue,	with	almost	no	nonspecific	background	staining	(N	=	3,	n	=	4).	N	=	total	number	of	 animals,	 and	n	 =	 total	 number	 of	 slices	 used.	 Imaged	at	 ex:	870	 nm,	 em:	555-605.	60x	magnification,	4x	optical	zoom.	(Scale	bars:	10	μm.)								
									
	




























































3-4).			 Taken	 together,	 these	 results	 suggest	 that	 the	 neutravidin	 and	 previously	discussed	PEG	polymers,	but	not	the	quantum	dot,	may	be	suitable	platforms	for	targeted	













































delivery	to	specific	cells	in	living	brain	tissue.	The	PEG	polymer	and	neutravidin	protein	represent	two	classes	of	diffusible	constructs	that	may	be	conjugated	to	a	homing	ligand	and	 functionalized	 to	 deliver	 other	 loads	 to	 specific	 cellular	 targets.	 However,	 their	potential	 use	 as	 delivery	 platforms	 is	 not	 without	 limitation.	 High	 background	fluorescence	signals	resulting	from	poor	tissue	clearance	(for	example:	DumPSN,	Figure	
3-7	D)	as	opposed	to	cell-specific	 labeling	may	confound	the	analysis	of	how	effective	a	targeted	probe	 is	at	diffusing	 to	and	binding	 its	 target	 receptor.	Thus,	 it	 is	necessary	 to	distinguish	signals	specific	to	the	cellular	target	from	total	(specific	+	nonspecific)	signal.	Doing	so	would	enable	a	more	viable	approach	for	assessing	receptor-targeting	ability	of	a	diffusible,	targeted	probe.	
II.5		 Determining	DAT	Specificity	of	Targeted	Probes	in	Living	Brain	Tissue		
	 An	 important	 consideration	 in	 targeted	 delivery	 of	 (macro)molecules	 to	 brain	tissue	is	the	need	to	achieve	concentrations	high	enough	to	elicit	the	desired	response	at	the	desired	cellular	target(s).	The	concentration	of	a	diffusing	substance	diminishes	with	increasing	 distance	 from	 the	 site	 of	 release,	 and	 with	 increasing	 time,	 as	 previously	discussed.	Affinity-based	interactions	of	a	diffusible	molecule	with	a	cellular	target	serve	to	both	reduce	the	rate	at	which	the	molecule	diffuses	through	the	tissue	and	to	retain	the	molecule	at	the	target	sites	within	the	tissue	(see	Figure	3-8,	E,	F	for	a	graphic	example).	The	extent	of	 tissue	distribution	and	retention	are	affected	by	molecular	weight	 (which	affects	D*)	and	probe-receptor	affinity	(which	contributes	to	a	binding-site	barrier	effect).	The	question	remains	whether	a	targeted	macromolecule	can	achieve	concentrations	high	enough	at	distances	r	from	the	release	site	to	illicit	a	desired	response	within	a	reasonable	
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time	frame.	To	answer	this	question,	we	analyzed	the	extent	to	which	the	tropane	tagged	molecules	specifically	labeled	dopaminergic	axons	at	several	distances	in	tissue,	over	time	(Figure	3-11).		At	15	μm	below	the	tissue	surface,	the	specific	signal-to-background	(S/B)	ratio	of	ECN127	targeting	to	dopaminergic	axons	is	2.96	±	1.24	(at	1.9	minutes).	This	value	does	not	significantly	change	by	the	end	of	the	experiment	[S/B	=	3.67	±	1.15	(mean	±	std)	at	t	=	43.4	minutes,	p	=	0.203,	Welch’s	two-tailed	t	 test;	Figure	3-11,	A],	demonstrating	the	high	affinity	of	ECN127	 for	DAT.	Though	 the	macromolecules	PSN102	and	DNB	require	
Figure	3-11.	Specific	labeling	of	dopaminergic	axons	in	mouse	dorsal	striatum	with	tropane-tagged	
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more	 time,	 they	 also	 reach	 a	 specific	 S/B	 similar	 to	 that	 of	 ECN127	 by	 the	 end	 of	 the	experiment	[PSN102	=	3.20	±	0.72,	DNB	=	4.65	±	2.01,	(mean	±	std),	Figure	3-11	B,	C].	Further,	the	fluorescence	signals	for	PSN102	and	DNB	appear	to	still	be	increasing	by	the	end	of	the	experiment.	In	particular,	the	average	S/B	trend	for	DNB	at	−15	μm	and	43.4	minutes	 suggests	 that	 greater	 S/B	 can	 be	 achieved	 with	 the	 polyvalent	 DNB	 probe	 in	comparison	 to	 the	monovalent	 small	molecule	 ECN127	 (Figure	 3-11).	 This	 is	 possibly	because	 there	 are	 an	 average	 of	 two	 fluorophores	per	 “molecule”	 of	DNB,	 compared	 to	only	 one	 for	 both	 ECN127	 and	PSN102.	 Thus,	 the	 local	 concentration	 of	 fluorophore	 is	doubled	at	“each	DAT,”	resulting	 in	a	higher	signal-to-background	when	measured.	This	data	 demonstrates	 the	 potential	 power	 of	 polymer	 platforms	 for	 targeted	 delivery.	Polymers	 amenable	 to	 chemical	 modifications	 could	 be	 functionalized	 with	 multiple	ligands	 and	 multiple	 reporters	 (or	 beacons)	 for	 delivery	 to	 a	 single	 site(s),	consequentially	 enhancing	 the	 cellular	 detection	 or	 therapeutic	 response	 at	 that	 site.	Enhanced	detection	would	be	 especially	 important	 at	 distances	 further	 from	 the	 site	 of	introduction,	where	concentrations	of	tagged	probe	would	be	lower.		For	 all	 the	 molecules,	 the	 macromolecules	 in	 particular,	 the	 S/B	 decreases	 at	greater	depths	from	the	surface	(Figure	3-11,	data	not	shown	for	PSN102	and	DNB).	This	is	possibly	due	to	decreased	penetration	of	the	tagged	probe	with	distance.	(Note:	The	2-photon	 laser	 power	 decreases	 with	 increasing	 tissue	 depth.	 This	 decrease	 in	 laser	penetration	may	 also	 contribute	 to	 the	 apparent	 reduction	 in	 S/B.)	 At	 50	 μm	 from	 the	surface,	fluorescence	signal	specific	to	dopaminergic	axons	cannot	be	detected	with	any	of	the	 tagged	 probes,	 even	 almost	 45	 min	 after	 probe-tissue	 ejection.	 As	 previously	mentioned,	Nicholson18	reports	that	the	nearest	parenchymal	brain	cell	is	separated	from	
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blood	vessels	by	~50	μm.	Thus,	diffusion	across	distances	of	50	μm	from	sites	of	entry	is	an	 important	 requirement	 for	 targeted	 delivery	 of	 macromolecular	 probes	 across	 the	blood-brain	barrier	or	from	arteriolar	paravascular	spaces.		The	level	of	specific	signal-to-background	attained	for	each	probe	will	depend	on	the	concentration	applied	to	the	slice.	Inadequate	clearance	of	a	probe	applied	at	too	high	a	concentration	would	result	 in	a	 low	S/B,	confounding	conclusions	drawn	about	probe	specificity	for	the	target.	Thus,	a	dose-response	is	needed	for	each	probe	to	determine	the	concentration	 resulting	 in	 the	 best	 signal-to-background	 ratio.	 Preliminary	 results	obtained	for	ECN127	in	the	dorsal	striatum	are	shown	in	Figure	3-12.	ECN127	in	ACSF	was	perfused	 over	 acute	 slice	 at	 three	 different	 concentrations.	 The	 specific	 labeling	 of	dopaminergic	 axons	was	 determined	 at	 the	 same	 time	 point	 and	 tissue	 depth	 for	 each	concentration.	 Preliminary	 data	 suggests	 that	 S/B	 trends	 towards	 decreasing	 with	increasing	ECN127	concentration	(Figure	3-12,	n	=	2	slices	for	each	concentration).	Thus,	a	2-fold	higher	concentration	of	this	high-affinity	DAT	ligand	applied	to	brain	tissue	would	
Figure	 3-12.	 Dose-response	 for	 ECN127.	 ECN127	 in	 ACSF	 was	 perfused	 over	 acute	 slices	 at	 three	different	 concentrations.	 The	 specific	 labeling	 of	 dopaminergic	 axons	 at	 -15	 μm	 below	 surface	 was	determined	 at	 the	 same	 time	 point	 and	 tissue	 depth	 for	 each	 concentration.	 (n	 =	 2	 slices	 for	concentrations	100	and	200	nM,	1	slice	for	50	nM.)	
























































































falsely	suggest	that	the	DAT	ligand	had	a	low	DAT-specificity	upon	analysis.	Future	dose-response	 curves	will	 be	 obtained	 for	 the	macromolecular	 probes.	We	 expect	 that	 these	experiments	will	 reveal	 the	 concentrations	at	which	 the	maximum	S/B	 is	 attainable	 for	each	of	these	tagged	probes.	
II.6	 An	Important	Note	About	Fluorescence	Signals	at	Large	Depths	from	Surface		It	 is	 important	to	note	that	the	majority	of	 the	diffusion	data	obtained	here	were	from	 an	 experimental	 set-up	 mimicking	 diffusion	 from	 a	 point-source.	 That	 is,	 ~100	nanoliters	 of	 probe	 at	 different	 concentrations	was	 applied	 to	 the	 slice	 surface	 from	 a	nanoject	 needle,	 the	 “point-source,”	 approximately	 3-5	 μm	 in	 diameter.	 Alternatively,	these	diffusion	experiments	could	have	been	performed	using	a	perfusion	set-up	similar	to	 that	used	 to	obtain	 the	dose-response	data	above	 (Figure	 3-12).	A	perfusion	 set-up,	which	 mimics	 planar	 diffusion,	 results	 in	 a	 constant	 application,	 or	 perfusion,	 of	 the	tagged	 probe	 to	 the	 entire	 tissue.	 This	 constant	 perfusion	 of	 tagged	 probe	 means	 a	continuous	increase	in	the	number	of	moles	of	probe	introduced	to	the	tissue.	This	is	 in	contrast	to	the	nanoject	set-up	that	delivers	a	set	number	of	moles	of	tagged	probe	to	the	tissue.	 Consequently,	 it	 is	 likely	 that,	 within	 the	 same	 time	 frame,	 a	 perfusion	 set-up	would	 result	 in	 increased	 probe	 concentration	 and,	 thus,	 better	molecular	 targeting	 at	distances	further	from	the	tissue	surface,	as	suggested	by	equation	5.		Additionally,	longer	imaging	times	could	be	used	to	determine	the	extent	of	probe-DAT	labeling	at	large	distances	from	the	slice	surface.	The	ex	vivo	technique	employed	for	these	 diffusion	 experiments	 is	 time-limited,	 however,	 as	 slice	 viability	 decreases	 with	time.	In	vivo	application	of	these	tagged	probes	to	brain	tissue,	however,	could	overcome	
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the	 limitations	 of	 maximum	 S/B	 attainable	 at	 the	 concentrations	 used.	 Alternatively,	 a	dose-dependence	study	could	provide	more	information	of	the	maximum	S/B	attainable	for	each	of	these	tagged	probes.	
II.7		 Preliminary	Results	from	the	Mouse	Cortex	
	 Dr.	 Matthew	 Dunn	 and	 Jihang	 Wang	 conducted	 preliminary	 two-photon	microscopy	experiments	 in	 the	mouse	barrel	 cortex	using	ECN127.	ECN127	 (200	–	300	nM)	 was	 bath-	 loaded	 through	 a	 cranial	 window	 onto	 the	 barrel	 cortex	 of	 a	 live,	anesthetized	mouse	and	imaged.	ACSF	perfusion	began	65	minutes	after	ECN127	loading	to	wash	away	unlabeled	dye.	Images	were	acquired	10	minutes	after	wash	began	(Figure	















































Figure	3-13.	ECN127	in	live	mouse	barrel	cortex.	ECN127	(200-300	nM)	in	ACSF	was	bath	loaded	onto	the	barrel	cortex	of	a	live,	anesthetized	mouse	for	65	min,	then	washed	with	ACSF	for	10	min.	Images	were	acquired	through	an	open	cranial	window.	(A)	50	μm	and	(B)	~100	μm	from	surface.	Preliminary	images	are	 courtesy	 of	 Dr.	 Matthew	 Dunn	 and	 Jihang	 Wang.	 Arrows	 indicate	 labeling	 with	 ECN127	 possibly	consistent	with	the	anatomy	of	noradrenergic	fibers	in	the	rodent	cortex.		
A	 	 	 	 				 						B	 	
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III. CONCLUSIONS	AND	OUTLOOK			
	 As	mentioned	 earlier,	 the	 desire	 to	 target	 specific	 cells	 in	 the	 living	 brain	 tissue	coupled	with	our	on-going	 interests	 in	 the	dopamine	reward	pathway	 led	 to	 the	search	for	a	small	molecule	ligand	that	would	bind	to	DAT	with	high	affinity	and	high	specificity.	To	 begin,	 we	 synthesized	 and	 evaluated	 a	 small,	 fluorescent	 tropane-based	 ligand,	ECN127,	 and	 confirmed	 its	 high	 affinity	 at	 DAT,	 as	 well	 as	 its	 utility	 in	 our	 various	biological	systems	(cell	culture,	ex	vivo	tissue	culture,	in	vivo	mouse	brain).	In	addition	to	its	 high	 DAT	 affinity,	 we	 found	 that	 ECN127	 also	 demonstrates	 high	 affinity	 for	 the	norepinephrine	 transporter	 (NET)	 in	 cultured	human	embryonic	kidney	 (HEK)	cells.	As	such,	 we	 applied	 ECN127	 to	 the	 rodent	 cortex,	 which	 is	 heavily	 innervated	 with	 NET	neurons,	 and	 observed	 labeling	 consistent	with	 the	 anatomy	 of	 noradrenergic	 fibers	 in	this	region.	Because	the	dorsal	striatum,	the	anatomical	brain	region	heavily	 innervated	with	 DAT-expressing	 neurons,	 is	 difficult	 to	 access	 using	 2-photon	 microscopy	 in	 the	living,	in-tact	brain,	in-vivo	use	of	ECN127	and	polymer-derived	probes	may	be	limited	to	the	cortex.	Having	confirmed	the	utility	of	the	small	molecule	tropane	tag	at	both	DAT	and	NET	 across	 different	 biological	 systems,	 we	 sought	 to	 develop	 a	polymeric/macromolecular	 tropane-conjugated	 platform	 that	 could	 target	 DAT	 in	 the	living	brain	 and	deliver	 other	 functional	 probes	 to	DAT-expressing	 cells.	At	 this	 time,	 a	similar	high	affinity	of	the	tropane-based	macromolecular	probes	for	NET	would	also	be	beneficial	for	our	in	vivo	imaging	purposes.					After	 testing	 the	 commercially	 available	 streptavidin	 quantum	 dot	 in	 vivo	 as	 a	possible	delivery	platform,	we	discovered	what	others	had	suggested,	namely,	that	these	materials	were	ill-suited	for	biological	applications	in	living	brain	tissue	due	to	their	poor	
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	 Experiments	were	carried	out	at	 the	Columbia	University	Medical	Center.	Animal	protocols	 were	 approved	 by	 Columbia	 University’s	 Institutional	 Animal	 Care	 and	 Use	Committee	 (IACUC).	 Animals	 used	 were	 7-12	 week	 old	 male	 wild-type	 C57BL/6	 mice	obtained	from	the	Jackson	Laboratory.			 Mice	were	decapitated	and	acute	300-μm	thick	corticostriatal,	coronal	slices	were	cut	using	a	microvibratome	and	allowed	to	recover	at	 room	temperature	 in	oxygenated	(95%	O2,	 5%	CO2)	 artificial	 cerebral	 spinal	 fluid	 (ACSF,	 in	mM:	 125.2	NaCl,	 2.5	KCl,	 26	NaHCO3,	0.3	KH2PO4,	2.4	CaCl2,	1.3	MgSO4,	10	Glucose,	0.8	NaH2PO4	monohydrate,	pH	7.2-7.4,	305-310	mOsm.)	for	at	least	45	minutes	prior	to	imaging.	Slices	were	used	within	1-5	hours	after	sacrifice	of	the	mouse.			
IV.2		 Nanoject	Loading	and	2-photon	Imaging	of	Molecular	Probes		
	 Probes	were	loaded	into	a	micropipette	(tip	diameter	3	–	5	μm)	using	a	Nanoject	II	Auto-Nanoliter	Injector	(Drummond	Scientific).	Concentrations	of	probes	used	were:	200	nM	ECN127	and	OH-RRX,	5	μM	PSN102	and	DumPSN,	10	μM	DNB	and	DumNB	(average	of	2	tropane	or	dummy	tags	and	2	BiocytinAlexafluor	fluorophores	per	1	neutravidin),	and	500	 nM	 Tagged	 and	 Untagged	 QD	 (2:1	 molar	 ratio	 of	 tropane	 or	 dummy	 tag	 to	streptavidin	 quantum	 dots605;	 QD605,	 Invitrogen),	 as	 solutions	 in	 ACSF.	 For	 diffusion	measurements	in	brain	tissue,	ACSF	was	perfused	over	brain	slices	at	room	temperature	in	 a	 chamber.	 Probes	 were	 ejected	 onto	 tissue	 using	 the	 Nanoject	 II	 (2	 x	 50.6	 nL,	sequentially,	 at	 a	 rate	 of	 46	 nL/	 sec)	 after	 a	 sequence	 of	 background	 images	 were	
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acquired,	and	imaged	for	43.4	minutes	post	ejection.	Images	were	acquired	on	a	Leica	SP5	confocal/multiphoton	 microscope	 with	 a	 titanium-sapphire	 MaiTai	 laser	 (Spectra	Physics)	equipped	with	a	60X,	0.9	NA	water	immersion	objective.	Probes	were	excited	at	870	 nm	 and	 fluorescence	 emission	 acquired	 between	 555	 –	 605	 nm.	 Images	 were	collected	at	 a	 resolution	of	512	x	512	pixels	 (52	μm	x	52	μm).	All	 probes	were	 imaged	from	the	slice	surface	to	a	depth	of	50	μm	below	the	surface,	at	5	μm	steps.		
IV.3		 Quantification	of	Probe	Tissue	Penetration		Images	were	analyzed	using	 ImageJ	 software	 (National	 Institutes	of	Health).	The	total	 fluorescence	 at	 each	 depth	 for	 each	 image	 analyzed	 was	 normalized	 to	 the	fluorescence	at	 the	 top	slice	(z	=	0	μm)	at	 the	 first	observable	 time	after	probe	ejection	onto	slice.	For	example,	raw	fluorescence	values	shown	in	Table	3-2	were	normalized	as	shown	in	Table	3-3.								
ECN127,	N=1	
Time	
(min)		 0		 -5	 -10	 -15	 -50	
Normalized		 -3.83	 507.62092	 611.25394	 389.68744	 284.76514	 216.11294	
to	
fluorescence		 0	 2390.9143	 2730.9839	 1967.4092	 1257.2549	 239.0284	
at	"0	min"		 1.9	 1807.1467	 2312.1758	 1924.0214	 1538.6123	 246.2012	
and	0	μm	 14.7	 1255.5735	 1786.0166	 1633.3422	 1426.5078	 272.7446	
		 30	 1094.3235	 1584.92	 1481.3516	 1325.1124	 305.6145	







	 To	 generate	 plots	 for	 tissue	 retention	 or	 clearance	 (Figure	 3-8,	 E-F),	 the	 area	under	 the	 FTot/F0	 x	 Distance	 (μm)	 curves	 for	 each	 time	 point	 in	Figures	 3-8	 A-D	 was	calculated	 using	 Graph	 Pad	 Prism	7	 software.	 For	 each	 probe,	 the	 total	 area	 under	 the	curve	 (AUC)	 calculated	 was	 plotted	 against	 time	 to	 determine	 the	 extent	 of	 tissue	retention	or	clearance	over	time.	
IV.4		 Measurement	of	Specific	Signal-to-Background	Ratio			 Images	were	 analyzed	using	 ImageJ	 software	 (National	 Institutes	 of	Health).	 For	each	 probe,	 images	 at	 specific	 time	 points	 were	 stacked	 together	 and	 the	 contrast	adjusted,	though	not	applied	to	the	images,	to	better	distinguish	the	specific	fluorescence	signal	 from	 background.	 The	 images	 were	 converted	 to	 8-bit	 images	 for	 analysis.	 No	background	was	subtracted	 from	the	 images.	Beginning	with	 the	 last	experimental	 time	point,	 43.4	 minutes	 post	 probe	 ejection,	 a	 region	 of	 interest	 (ROI)	 was	 drawn	 around	objects	 presumed	 to	 be	 dopaminergic	 projections	 (Figure	 E1)	 and	 the	 average	 pixel	intensity	within	the	ROI	was	measured.	The	same	shaped	ROI	was	used	to	find	presumed	
ECN127,	N=1	
Time	
(min)		 0		 -5	 -10	 -15	 -50	
Normalized	 -3.83	 0.21231247	 0.223821876	 0.198071372	 0.226497538	
	to	
fluorescence	 0	 1	 1.142234124	 0.822868975	 0.525846911	 0.099973638	
at	"0	min"	 1.9	 0.755839178	 0.967067619	 0.804722026	 0.643524655	 0.102973662	
and	0	μm	 14.7	 0.525143666	 0.747001513	 0.683145439	 0.596636943	 0.11407544	
		 30	 0.457700847	 0.662892852	 0.619575365	 0.554228313	 0.127823277	
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